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Abstract 
 
CD8
+
 T cells play a major role in controlling infection and disease progression in 
many infectious diseases. Upon infection, antigen-specific CD8
+
 T cells are generated 
and mainly through their cytotoxic activity remove infected cells, therefore, pathogens. 
Ongoing research has identified antigenic epitopes in a vast number of pathogens and, 
using the identified epitopes, the induction of CD8
+
 T cell immune responses has been an 
important strategy for successful vaccines. However, most immunization approaches with 
class I binding peptides have failed to induce CD8
+
 T cell responses strong enough to 
prevent disease. This failure has been attributed to the lack of CD4
+
 T cell help and 
difficulty in maintaining a sufficient level of antigen presentation required for CD8
+
 T 
cell activation. To circumvent these limitations, we have developed fully assembled MHC 
molecules that can be expressed as membrane-bound proteins on the cell surface, termed 
single chain trimers (SCTs). SCTs are composed of an immunodominant peptide, 2m, 
and MHC I heavy chain covalently linked by 15-20 amino acid flexible linkers. Because 
SCTs are expressed as a single polypeptide chain, they do not require peptide processing, 
or chaperone-assisted peptide loading in the ER. Furthermore, antigen presentation by the 
SCT bypasses the need to compete with an extensive pool of endogenous peptides for 
peptide loading. SCTs are folded properly and T cells see SCTs comparably to native 
peptide/MHC I complexes. Various human and mouse class Ia and Ib MHC molecules 
have been engineered with epitope peptides into SCTs and proven as useful tools to 
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monitor and modulate immune responses. Thus, SCT engineering offers a great potential 
as a platform for antigen-specific DNA vaccines. Although there have been several 
reports of SCT-based DNA vaccines generating antigen-specific CTL responses, there 
have been no reports of pathogen protection after DNA vaccine expression of SCTs. In 
this thesis, I examined the efficacy of SCT DNA vaccines for the first time in pathogen 
infection models. First, we developed a clinically relevant human HLA-A2 transgenic 
mouse model of West Nile virus (WNV) infection and demonstrated protective efficacy 
of a HLA-A2 SCT DNA vaccine against lethal viral infection. Second, I validated the 
potency of a SCT DNA vaccine using the BALB/c model of Listeria monocytogenes 
infection, which indicated that SCT DNA vaccines also provide protective immunity 
against bacterial infection. Lastly, I demonstrated that further engineering of SCTs 
(dtSCT) using a disulfide trap to better accommodate epitopes can potentiate the capacity 
of SCTs to stimulate CD8
+
 T cells, suggesting broad application of SCTs even with low 
immunogenic peptides. I also used disulfide trap- or chimeric SCTs to test the mechanism 
of antigen presentation after DNA vaccination. My studies showed that SCTs are 
presented to T cells as intact molecules after DNA immunization, suggesting direct 
presentation by transfected DCs or cross-dressing as a major mechanism of the antigen 
presentation by DNA vaccine. In summary, these dissertation studies demonstrated that 
SCT-based DNA vaccines can provide pathogen protection and SCTs are effective probes 
for dissecting mechanisms of antigen presentation. 
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Chapter 1 
Background and Significance 
 
Vaccination is the most effective method of preventing infectious diseases. Most 
of the vaccines developed to date have focused on humoral immunity, i.e. production of 
antibodies for neutralizing viruses and toxins or opsonizing bacteria. However, there are 
many cases in which the antibody response is not the best effector arm of the immune 
system to protect against pathogens. This is where T cell immunity comes into play. 
CD8
+
 T cells also have a significant function in immunity against pathogens. Cytotoxic 
CD8
+
 T lymphocytes (CTLs) kill the infected cells and/or release cytokines that inhibit 
growth of the microbe or impair the ability of the pathogen to survive inside the cell. For 
example, cytotoxic memory CD8
+
 T cells have been found in several model systems to 
have prominent roles in the clearance of virus by producing antiviral cytokines or lysing 
virus-infected cells. Thus efforts have been made to generate vaccines that can elicit 
effective CD8
+
 T cell responses [1, 2]. Mechanistically generation of effective CD8
+
 T 
cell responses requires the delivery of antigen into the appropriate antigen presentation 
pathway to stimulate major histocompatibility complex I (MHC class I)-restricted CTL 
responses. Although it is possible to elicit CD8
+
 T cell responses against intact or 
attenuated pathogens, this approach rarely elicits optimal CD8
+
 T cell responses. 
Alternatively, it is considered more attractive to immunize only against the specific 
antigens that elicits efficacious anti-pathogen CD8
+
 T cell immune responses. However 
this approach requires knowing the immunodominant pathogen-specific antigens 
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presented by MHC-disparate individuals. Fortunately, there are now several computer 
programs that reliably predict peptide binding to different MHC alleles, and the genomes 
of several pathogens have continued to be sequenced. Thus bioinformatic analysis of a 
pathogen genome can be used to comprehensively identify pathogen-specific potential 
epitopes for CD8
+ 
T cells in silico. Such predicted epitopes for CD8
+
 T cells can then be 
tested experimentally by showing they are capable of specific ex vivo re-activation of 
CD8
+
 T cells from infected patients or animals. However, unfortunately, 
immunodominant peptides have not been particularly effective in stimulating primary 
CD8
+
 T cell immune responses in vivo, thus limiting their vaccine applications. There are 
no currently available peptide-based or plasmid DNA vaccines encoding only 
immunodominant CD8
+
 T cell epitopes. However, using tumor models there is recent 
evidence by Melief and colleagues that long peptides extended beyond the minimal 
MHC-binding epitope may be effective as vaccines because of prolonged, dendritic cell-
focused antigen presentation [3-8]. 
Failure to elicit a robust CD8
+
 T cell response after immunization with class I 
peptide epitopes in part stems from the lack of concomitant help from CD4
+
 T cells. In 
several experimental systems CD4
+
 T cell help is required for generating and sustaining 
long term CD8
+
 T cell memory. An additional problem with immunizing with class I 
binding peptides by themselves is the difficulty in maintaining a sufficient level of 
antigen presentation required for CD8
+
 T cell activation. As briefly mentioned above, 
CD8
+
 T cells see antigens in a form of MHC I/peptide complexes. MHC molecules are 
composed of a heavy chain and 2-microglobulin (2m) and bind peptides from self or 
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from pathogen-infected or transformed cells, and present them on the cell surface to 
CD8
+
 T cells. Multiple cellular and molecular processes are required for cell surface 
expression of MHC I/peptide complexes [9]. Peptides suitable for MHC I binding are 
generated in the cytosol by the proteasome which generates peptides of 10-20 amino 
acids that are transported into the endoplasmic reticulum (ER) via TAP 1/2 (transporter 
associated with antigen processing). In the ER, peptides can be further trimmed at the N-
terminus by aminopeptidases for MHC I binding. Then the peptide loading complex 
(PLC) in the ER facilitates assembly of the MHC I/peptide complex and consists of TAP, 
ERp57, and the molecular chaperones, tapasin and calreticulin along with MHC I heavy 
chain and 2 microglobulin. Once a suitable peptide, typically 8-10 amino acids, binds to 
the binding groove of MHC I, the complex is released from the PLC and transits to the 
cell surface. Because this antigen processing and presentation pathway involves several 
complex molecular interactions, it can be inefficient, particularly for certain 
MHCI/peptide complexes. Furthermore, MHC molecules do not discriminate self from 
non-self peptides, and the antigenic peptide must compete with an extensive pool of 
endogenous peptides for loading onto MHC class I molecules and presentation to CD8
+
 T 
cells. Furthermore, peptide dissociation can occur post ER assembly, which lowers the 
steady state level of specific MHCI/peptide complexes at the plasma membrane. This 
results in insufficient MHC I/peptide complexes displayed at the cell surface for CD8
+
 T 
cell priming after epitope vaccines. Thus, antigenicity of vaccines for T cell responses 
can be enhanced by improving processing, abundance, or MHC binding of peptides.  
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To circumvent limitations of antigen processing and presentation, we and others 
have engineered fully assembled MHC molecules that can be expressed as membrane 
proteins on the cell surface [10, 11]. These fully assembled MHC molecules, termed 
single chain trimers (SCTs), are composed of an immunodominant peptide, a flexible 
linker of 15 or 20 amino acids that connects the C terminus of the peptide to the N 
terminus of 2m, and a second flexible linker that connects the C terminus of 2m to the 
N terminus of the heavy chain of a given class I MHC molecule. We chose to attach the 
components in this order because i) based on the crystal structures, the C-terminus of 
peptide ligand is more accessible than the N-terminus deeply buried in the peptide 
binding groove and unusual peptides with a few additional residues at the C-terminal end 
have been isolated, ii) the crystal structure of MHC I predicts a more direct path for the 
linker from the peptide to the N terminus of 2m than to heavy chain [10-12]. Flexible 
linkers are based on the Gly-Gly-Gly-Gly-Ser motif that was used previously to produce 
single chain MHC molecules or immunoglobulins by others [10, 13]. Lengths of the 
linkers were determined, also based on the crystal structure, to be 10-20 amino acids and 
the study in our lab showed that the linker combination of 15 and 20 amino acids results 
in better recognition by T cells [11]. While coupling of peptide ligand to the heavy chain 
[10] and peptide to free 2m [12, 14, 15] have been previously reported by others, it was 
applicable only to select MHC I/peptide complexes and is not clear how efficiently it can 
exclude the binding of competing peptides. On the contrary, our SCTs have been 
successfully applied to most mouse, rat and human MHC I/peptide complexes tested so 
far, suggesting its application is universal. However, in this thesis work, we found that the 
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SCT construct does not work with every MHC I/peptide complex and this exception 
raised questions about whether SCTs with difficult peptides can be improved, which is 
important for vaccines for diseases where antigenic peptides have poor immunogenicity.  
To probe structural and functional properties of SCTs, our lab has used the H-
2K
b
/OVAp SCT as a model. These comprehensive characterizations of the K
b
/OVAp SCT 
have shown that the SCT has several properties described below that have potentiated 
their use as DNA vaccines as well as in studies of lymphocyte biology [11, 16-24]. Cell 
surface staining with a monoclonal antibody (mAb) specific for folded K
b
 as well as mAb 
25D-1.16 that specifically recognizes K
b
/OVAp complexes showed that SCTs are 
expressed at a high level with native folding at the cell surface[11]. OT-1 T cells that are 
specific for K
b
/OVAp also recognized SCTs. Biochemical analyses using western blot 
revealed that SCTs maintain their intact covalent structure in cells. Covalent peptide 
binding in the SCT makes it less accessible to loading by exogenous competitor peptides. 
As a result, K
b
/OVAp SCTs were very resistant to displacement by a high concentration 
of exogenous peptide in a peptide competition assay. They are also more stable at the cell 
surface than native MHC I/peptide complexes and exhibit an extended cell surface half-
life. In vivo, K
b
/OVAp SCTs retained their native MHC/peptide structure, and were thus 
able to stimulate antibody specific for K
b
/OVAp by DNA vaccination. Cells expressing 
SCTs were detected by CTLs generated to native MHC I/peptide complexes, and CTLs 
generated to cells expressing SCT detect target cells expressing native MHC I/peptide 
complexes. Furthermore tetramers constructed with SCTs reliably stained the same T 
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cells as conventional tetramers. Thus T cells appear to detect SCTs indistinguishably 
compared to native MHC I/peptide complexes. 
The MHC I peptide binding groove formed between the 1 and 2 domains of 
the heavy chain is closed and accommodates a certain length of peptides that does not 
extend beyond the binding groove. Because the interactions between the C terminus of 
peptide and conserved residues of heavy chain at the end of the binding groove are 
critical for stable peptide anchoring, in SCTs a linker extended from the C terminus of the 
peptide is predicted to abolish these conserved interactions and interfere with optimal 
peptide anchoring. In fact, K
b
/OVAp SCTs exhibit lower reactivity with the antibody 
specific for K
b
/OVAp complexes than native K
b
 loaded with exogenous OVAp. Also 
OVAp in the SCTs was more easily displaced with a high concentration of competing 
peptides than was the peptide bound to native K
b
. Despite this impaired peptide binding, 
K
b
/OVAp SCT is more stable than native MHC I/peptide complexes and exhibits a high 
level of steady state peptide occupancy because the covalently attached peptide 
efficiently rebinds after dissociation. Although this was not a problem for tight binding 
peptides like OVAp, weak binding peptides would be more dependent on peptide 
rebinding. Thus our lab in collaboration with the Fremont lab took a structure based 
approach to understand how the SCT binds peptide and accommodates the linker with the 
purpose to use this knowledge to engineer improvements to the SCT. 
The crystal structure of K
b
/OVAp SCT revealed that OVA peptide is bound in the 
MHC I peptide binding groove in a canonical manner where the anchoring residues, P2, 
P5, and P8 are buried and pointed toward the -sheet platform of the groove. However, in 
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the F pocket of the peptide binding groove of the SCT, the peptide-2m linker extrudes 
from the C terminal end of the groove and extends over a conserved TCR recognition 
region. Tyr
84
 in the K
b
 heavy chain, which creates the C-terminal wall in the F pocket and 
is involved in closing the C terminal end of the groove, precludes optimal linker 
positioning in the K
b
/OVAp SCT. Mutation of Tyr
84 
to Ala opened the C terminal end of 
the binding groove and created a channel to accommodate the peptide-2m linker without 
a big conformational change. This SCT
Y84A
 displayed enhanced surface stability with 
comparable T cell recognition to SCT
WT
 or native MHC I/peptide complexes [22, 25]. 
Our lab in collaboration with the Fremont lab further engineered SCTs by incorporating a 
disulfide trap in the F pocket area. Two mutations of Tyr
84 
to Cys and Gly
2
 of the peptide-
2m linker to Cys generated a disulfide bond that creates a unique F pocket hydrogen 
bond network without disturbing overall conformation of the complexes [23]. This 
disulfide trapped SCT (dtSCT) better accommodates the peptide-2m linker and very 
efficiently excludes competitor peptides from the peptide binding groove and preserves 
TCR interactions [23-25]. The disulfide trap engineering of SCT is also applicable to 
human MHC class I, HLA because Tyr
84
 is well conserved [24]. Thus the improved 
stability of dtSCT would have advantages over the original SCT (SCT
WT
) in the case of 
weak-binding peptides. Importantly, various human and mouse MHC class Ia and class Ib 
molecules have been engineered with epitope peptides into SCT and proven as useful 
tools to monitor and modulate immune responses [24, 26-33].  
Universal SCT engineering offers great potential as a platform for antigen-
specific DNA vaccines. Plasmid DNA as vaccine vectors has been developed and applied 
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against various pathogens because of its advantages; easy manipulation, relatively 
generic construction and production, fewer safety issues than other vectors such as viral 
vectors, and potential for sustained antigen delivery. However, despite its great success in 
small animal studies, DNA vaccines performed poorly in larger animal models including 
human clinical trials [2, 34-39]. While efforts have been made to improve antigen 
expression, potency and immunogenicity of DNA vaccines, SCTs have several properties 
that could potentiate the use of DNA vaccines. SCTs have been proven strongly 
immunogenic as DNA vaccines. When expressed by DNA immunization, SCTs elicit 
robust antigen specific CD8
+
 T cell responses in mouse model systems. The potency of 
SCT DNA vaccines has been convincingly demonstrated in mouse tumor models [30, 40, 
41]. For example, in a collaborative study between our lab and T. C. Wu and colleagues 
at Johns Hopkins university [30], mice vaccinated with DNA encoding a SCT of an 
immunodominant CTL epitope of human papilloma virus type 16 (HPV-16) E6 antigen 
and H-2K
b
 were protected against a lethal challenge of E6-expressing TC-1 tumor cells. 
Importantly, SCT-based DNA vaccines appeared more effective at generating CD8
+
 T cell 
immunity than subunit or epitope-only DNA vaccines even when targeted to the ER 
lumen, due to incorporation of a preprocessed and preloaded peptide [21, 30, 31]. 
Furthermore, studies have demonstrated the flexibility of the SCT platform by combining 
it with other strategies to enhance DNA vaccine potency. For example, SCTs were co-
expressed with a universal CD4 helper T cell epitope to stimulate T helper cells that 
resulted in enhanced CD8
+
 T cell responses and anti-tumor effects [41]. However, tumor 
models used in those studies are not necessarily clinically relevant since the tumor cells 
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for mouse challenge were generated by transfection of cells with the protein that includes 
tumor antigens. Under physiological conditions, tumor cells can downregulate expression 
of MHC and target antigens to evade host immunity [34]. 
Despite promising studies in tumor models, there have been no reports of 
pathogen protection after DNA vaccine expression of SCTs. K. Gould et al. showed that a 
recombinant vaccinia virus (rVV) expressing a H-2D
b
 SCT with influenza virus 
nucleoprotein [42] epitope can more efficiently prime peptide-specific CD8 T cells than 
rVVs expressing other forms of NP antigen [31]. But protection provided by SCT against 
pathogen infection has never been tested. A SCT platform as a DNA vaccine against 
pathogen infection is particularly attractive because antigen expression as a SCT is not 
susceptible to immune evasion mechanisms employed by pathogens. Pathogens have 
evolved mechanisms by which they can evade immune surveillance of the host. For 
example, human cytomegalovirus (HCMV) encodes the US3 protein, which binds to 
tapasin, a chaperone molecule in the peptide loading complex, and retains MHC I 
complexes in the ER [43, 44]. Thus down-regulation of surface MHC I molecules leads 
to decreased CD8
+
 T cell responses and benefits survival of virus in the host. Because 
expression of SCTs bypasses antigen processing and peptide transport, SCT DNA 
vaccines are expected to be resistant to several viral immune evasion mechanisms.  
Efficacy of DNA vaccines can be further increased by targeting the antigen 
expression to the compartment that plays a critical role in priming T cells. The exact 
mechanism by which DNA leads to antigen presentation capable of eliciting a T cell 
immune response has yet to be fully defined. Generally professional antigen presenting 
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cells, dendritic cells (DCs), are thought to present antigens and prime naïve CD8
+
 T cells 
after DNA vaccination, because DCs are equipped with co-stimulatory molecules which 
can activate naïve T cells in combination with TCR engagement [45-48]. However, it 
remains unclear whether T cell priming depends on antigen produced by DCs directly 
transfected with DNA that traffic to the draining lymph nodes to present antigens to T 
cells, antigen cross-presented by DCs that take up the antigens from transfected cells such 
as keratinocytes or myocytes, or antigen presented by both mechanisms. For example, 
Germain et al. demonstrated that after gene gun delivery of DNA, a small number of 
directly transfected DCs present in draining lymph nodes were predominantly involved in 
the induction of a T cell response. They showed this by using a -gal plasmid as an 
indicator of direct transfection and by examining whether the same cells required co-
expression of the antigen and co-stimulatory molecule to prime T cells [49]. On the other 
hand, DC-specific antigen expression using a CD11c promoter was not sufficient to 
induce T cell responses [50]. This is in agreement with a report that antigenic peptides 
expressed predominantly in nonlymphoid tissues are transferred to APCs to optimally 
stimulate immune responses [51]. More recent studies have focused on the importance of 
a subset of DCs, CD8+ DCs that are capable of cross-presenting antigens in the 
induction of a T cell response [52-55]. The importance of CD8+ DCs has been 
emphasized by studies examining CD8
+
 T cell priming in skin infection with herpes 
simplex virus type 1 (HSV-1). Among a variety of DC subsets, CD8+ DCs were shown 
to be the only population responsible for antigen presentation in the draining lymph 
nodes after infection [55, 56]. Importantly, Murphy et al. demonstrated that DCs from 
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mice deficient in CD8+ DCs by depletion of transcription factor Batf3, are defective in 
cross-presentation and these mice exhibit impaired anti-viral CTL responses and anti-
tumor responses, suggesting an important role of cross-presentation by CD8+ DCs in 
induction of CTL responses [54]. Also it was reported that migratory Langerin
+
 CD103
+
 
dermal DCs are able to cross-present viral and self-antigens and this subset was proposed 
to be related to splenic CD8+ DCs [54, 57]. Thus, antigen cross-presentation by CD8+ 
DCs might also be a mechanism for DNA vaccines. Indeed, our colleagues showed that 
Batf3
-/-
 mice do not mount T cell responses after DNA vaccination (Lijin Li, personal 
communication).  
As mentioned above, there are several studies that suggest that the pre-assembled 
nature of SCT makes it superior to non-processed or unassembled antigenic peptide alone 
as vaccines. One might envision that the SCT format would not be advantageous if cross-
presentation is the predominant mechanism of Ag presentation after DNA vaccination. 
However, this may not be the case. Interestingly, Bevan et al. recently demonstrated that 
DCs can obtain pre-formed MHC I/antigens complexes from the surface of virus infected 
cells and present them to T cells in vivo [58]. This alternative way of antigen presentation 
is referred to as ‘cross-dressing’ and has previously been shown in vitro [59-63]. 
Moreover, the transfer of plasma membrane fragments including proteins between 
lymphocytes, called trans-endocytosis or trogocytosis, has long been reported [64, 65]. 
This process allows rapid transfer of intact cell surface proteins between cells in contact 
with one another and transfer of intact MHC/peptide complexes from APC to T cells has 
been demonstrated although the molecular processes involved need to be clarified. Cross-
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dressing as a mechanism of antigen presentation of DNA vaccines is very attractive 
because many studies have implied that both direct- and cross-presentation occurs and 
antigen-expressing nonlymphoid cells influence the magnitude of a primary response [50, 
51, 66]. Also, Heath et al. demonstrated that blocking egress of migratory dermal DCs 
that do not present antigens substantially inhibits HSV-1 specific CTL priming after 
infection, suggesting that migratory dermal DCs transport and transfer antigens to lymph 
node resident CD8+ DCs for presentation [56]. If cross-dressing serves a critical 
mechanism in inducing T cell responses by DNA vaccines, usage of the SCT platform 
will greatly enhance vaccine efficacy. Therefore, elucidating the antigen presentation 
mechanism after DNA immunization is of importance in that it allows optimization of the 
potency of DNA vaccines by targeting the right compartment as well as choosing the 
suitable form for antigen delivery. 
In this thesis, I examined the efficacy of SCT DNA vaccines for the first time in 
pathogen infection models. First, we developed a clinically relevant human HLA-A2 
transgenic mouse model of West Nile virus (WNV) infection and demonstrated the 
protective efficacy of a HLA-A2 SCT DNA vaccine against lethal viral infection. Second, 
I validated the potency of SCT DNA vaccines using H-2K
d
 SCTs in the BALB/c model of 
Listeria monocytogenes infection, which indicates that SCT DNA vaccines also provide 
protective immunity against bacterial infection. Lastly, I demonstrated that further 
engineering of SCTs (dtSCT) using a disulfide trap to better accommodate epitopes can 
improve the capacity of SCTs to stimulate CD8
+
 T cells, suggesting a broad application 
of SCTs even with low immunogenic peptides. Also, using a disulfide trap- or chimeric 
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SCT in order to distinguish whether it’s being cross-presented, I also demonstrated that a 
SCT is presented to T cells as an intact molecule after DNA immunization, suggesting 
direct presentation by transfected DCs or cross-dressing as a major mechanism of antigen 
presentation by DNA vaccines. Therefore, these dissertation studies demonstrate that 
SCTs serve as a potent DNA vaccine platform as well as effective probes for dissecting 
mechanisms of antigen presentation. 
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Chapter 2 
HLA-A2 SCT DNA vaccines in WNV infection 
 
Introduction 
To study the vaccine efficacy of SCTs against pathogen infection, we developed a 
HLA-A2 transgenic mouse model of West Nile virus infection (WNV). WNV is a 
mosquito-borne Flavivirus with an 11 kilobase single stranded RNA genome and contains 
a single open reading frame [67-71]. Infection in humans and other vertebrate animals 
can progress to paralysis, meningitis, encephalitis and death, especially in the elderly and 
immunocompromised individuals while the majority of infections are either 
asymptomatic or produce a mild febrile illness. Although the continued threat of WNV 
epidemics has stimulated vaccine development, there are currently no commercial human 
vaccines available. Both innate and adaptive immunity are implicated in protection 
against WNV. Cytotoxic T lymphocytes (CTL) play an important role in control and 
clearance of WNV infection, and recent studies in a murine model have suggested that 
induction of a strong CD8
+
 T cell immune response can enhance the protective activity of 
a WNV vaccine against challenge. Thus vaccines targeting CD8
+
 T cell immunity to 
WNV are clearly relevant and therefore WNV infection serves as a good animal model to 
test efficacy and probe the mechanism of SCT DNA vaccine to induce CD8
+
 T cell 
immunity for protection. 
Despite prior studies suggesting the protective role of CD8
+
 T cells against WNV 
infection, CD8
+
 T cell recognition epitopes were not reported until recently. A 
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collaborative study between the Diamond, Hansen and Fremont labs as well as a study by 
the Nikolich-Žugich lab defined dominant H-2Db and H-2Kb epitopes of WNV antigens 
[72, 73]. More specifically, a D
b
-restricted WNV epitope derived from the NS4B protein 
and a K
b
-restricted epitope from the envelope (E) protein were identified. Adoptive 
transfer of CTLs specific for these epitopes conferred partial protection against WNV 
infection in C57BL/6 mice. To extend these findings to humans, our collaborators in the 
Hildebrand lab at the University of Oklahoma eluted peptides from HLA-A0201 
molecules of WNV-infected HeLa cells [74]. Mass spectrometry approaches were then 
used to identify six WNV-derived peptides bound to HLA-A2. These six peptides were 
derived from five different WNV proteins demonstrating broad presentation of epitopes 
from the WNV proteome (Table 1). When tested with T cells from HLA-A2
+
 patients 
post WNV infection, one peptide was found to be immunodominant, two subdominant 
and three demonstrated no significant CTL response. The immunodominant peptide of 
WNV recognized by patients’ CTLs was SVGGVFTSV (designated as SVG9) that is 
derived from the E protein of WNV.  
To test the efficacy of an SCT-based vaccine incorporating the human WNV 
epitopes, we used the HLA-A2 transgenic mouse (HHDII) model. HHDII mice express a 
chimeric monochain of HLA-A*0201 (1/2 domains), mouse H-2 Db (3 domain) and 
linker-attached human 2m [75]. The mouse α3 domain was incorportated into the 
monochain to optimize interaction with mouse CD8
+
 T cells, whereas the human 2m 
was incorportated into the monochain to facilitate HLA-A2 expression. To restrict the 
development of CD8
+
 T cells to only HLA-A2, HHDII mice are also genetically deficient 
16 
 
in D
b
 and mouse 2m. Thus these mice develop relatively few CD8+ T cells, but the 
CD8
+
 T cells that HHDII mice do develop are largely HLA-A2-restricted. HHDII mice 
have been widely used for preclinical vaccine studies against tumors and viruses.  
I show in this chapter that the SVG9 peptide of WNV demonstrates striking 
immunodominance in the HHDII mouse model in concordance with the published studies 
of HLA-A2
+
 patients with previous WNV infections. This concordance validates the 
HHDII model system for studies of SCT-based vaccine efficacy as well as factors that 
determine the immunodominance of viral epitopes detected by CD8
+
 T cells during viral 
infection. I also show in this chapter that the SVG9 peptide can be incorporated into a 
SCT format, that vaccination with plasmid DNA encoding the HLA-A2/SVG9 SCT 
stimulates a robust CD8
+
 T cell response, and this response confers protective immunity 
against lethal WNV infection in the absence of pre-existing antibody. These findings 
were published in a featured article in the Journal of Immunology and represent the first 
demonstration of the efficacy of SCTs in pathogen protection.  Also included in this 
chapter is unpublished data using novel T cell receptor (TCR)-mimic monoclonal 
antibodies to show that antigen presentation of WNV epitopes expressed in the ER lumen, 
such as SVG9, is TAP-dependent. This is an interesting finding because it suggests that 
SVG9 is not processed by cellular ER proteases, but by the proteasome in the cytosol. 
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Materials and Methods 
1. Viruses and Mice  
The WNV strain 3000.0259 was isolated in New York in 2000 and passaged once 
in C6/36 cells. The WNV-KUN strain (16-532) propagated in C6/36 cells has been 
described previously [73]. HHDII transgenic (B6; Cg-B2M
tm1Unc
 H2-D1
tm1Bpe
Tg (HLA-
A/H2-D/B2M)1Bpe) mice were obtained from Dr. Beatriz Carreno with permission of Dr. 
François A. Lemonnier (18). These mice express the transgene, Tg (HLA-A/H2-D/B2M) 
1Bpe, in a mixed background involving B2M
tm1Unc/tm1Unc 
and H2-D1
tm1Bpe/tm1Bpe
. For 
simplicity, these mice are designated HHDII mice for the rest of this dissertation. All 
mice were bred and housed at Washington University Animal Facility and all animal 
procedures were approved by the Animal Studies Committee at the Washington 
University. 
 
2. Virus infection 
For inoculation of mice, virus was diluted in Hanks’ balanced salt solution 
(HBSS) containing 1% heat inactivated fetal bovine serum (FBS). Mice were infected 
with 10
2
PFU of WNV subcutaneously by footpad injection. To detect viral epitopes 
presented after infection, primary human monocyte-derived dendritic cells at day 7 in 
culture with GM-CSF and IL-4 were plated at 1x10
6
 cells/mL/well in a non-tissue culture 
treated 6 well plate. The following day, cells were infected with WNV at a MOI 
(Multiplicity of Infection) of 3 for 48 hours before performing cell staining. HeLa or 
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HeLa A2 cells were plated at 2x10
5
 cells/well in a 6 well plate and, on the same day, 
infected with WNV at a MOI of 0.3 or 3 for 48 hours before staining. 
3. Antibodies and peptides 
The following mAbs were purchased from eBiosciences or BD Biosciences: anti-
mCD8 (53-6.7), rat IgG2a isotype control, anti-IFN, rat IgG1 isotype control, and PE-
conjugated goat anti-mouse Ig. PE-conjugated SVG9 peptide/HLA-A*0201 and control 
tetramer were obtained from the National Institute of Allergy and Infectious Diseases 
tetramer facility (Emory University, Atlanta, GA). T cell receptor mimic monoclonal 
antibodies (TCRm) that are specific for peptide/HLA-A2 complexes were generated by 
immunization of mice with tetramers of peptide/ HLA-A2: RL4D, RL14C, RL15A, or 
RL26A (Receptor Logic, Abilene, TX). Peptides were synthesized by and purchased from 
Sigma-Aldrich (St. Louis, MO).  
 
4. Flow cytometry  
IFN production and tetramer binding of splenocytes and surface expression of 
viral epitope/HLA-A2 complexes on virus-infected cells were monitored by flow 
cytometry. For intracellular IFN staining, splenocytes were stimulated in vitro with each 
peptide at 0.1g/mL in the presence of GolgiPlug (BD Biosciences, San Jose, CA) for 4 
hours at 37C. Cells were washed, stained with FITC-conjugated anti-CD8 mAb or rat 
IgG2a, and fixed with 1% paraformaldehyde (PFA). After washing twice with buffer 
containing 0.1% saponin, cells were stained with APC-conjugated anti-IFN mAb or rat 
IgG1. For tetramer staining, cells were stained with tetramers for 40 min at 37C, and 
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subsequently FITC-conjugated anti-CD8 mAb was added for an additional 20 min at 
4C. Propidium iodide (PI) was added shortly before flow cytometry to gate out dead 
cells. Cells were acquired on FACSCalibur and data were analyzed with FlowJo software 
(Tree Star, Ashland, OR). 
 
5. Detection of Viral Epitope/HLA-A2 complex Expression  
For controls, 10M of peptide was added to uninfected cells for the last hour. 
Cells were washed three times and incubated with TCRm, RL4D, RL14C, RL15A, or 
RL26A (mIgG2a) for 40 min on ice. After washing, cells were stained with PE-
conjugated goat anti-mouse Ig antibody (BD Biosciences). To confirm the infection, 
aliquots of cells were stained with anti-WNV envelope mAb, E24. Prior to flow 
cytometry, cells were fixed with 2% PFA. 
 
6. Generation of ICP47-expressing cell line 
Stable cell lines expressing ICP47 were generated with HeLa or HeLa A2 cells 
using retrovirus transduction. As an internal control for TAP function, the HLA-A2 
binding peptide, GVLPALPQV derived from human chorionic gonadotropin (hCG)-, 
was expressed in the cytosol by attaching ubiquitins in front of the peptide. Expression of 
this peptide in combination with HLA-A2 at the surface was detected by specific TCR 
mimic monoclonal antibody, RL4D. To produce retrovirus, human embryonic kidney 
cells 293T were transiently transfected with plasmids using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) according to manufacturer’s instruction and cell culture 
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supernatant containing retrovirus was collected. HeLa or HeLa A2 cells were selected 
and maintained under geneticin or puromycin (Life Technologies, Grand Island, NY) 
post-transduction. All cells were maintained in DMEM (Invitrogen) supplemented with 
10% FBS (HyClone Laboratories, Logan, UT), 2mM L-glutamine, 0.1mM non-essential 
amino acids, 1.25mM HEPES, 1mM sodium pyruvate, and 100U/mL 
penicillin/streptomycin (all from the Tissue Culture Support Center, Washington 
University School of Medicine, St. Louis, MO). 
 
7. CTL Assays 
For in vitro CTL assay, CTLs were generated from WNV-KUN immunized 
HHDII spleen cells after in vitro SVG9 peptide stimulation for 2-4 weeks. To perform a 
51
Cr release assay, target cells labeled with 0.2 mCi of 
51
Cr (PerkinElmer Life Sciences, 
Wellesley, MA) were incubated with CTLs with or without peptides for 4 ½ hours at 
37C. To determine maximum lysis, Triton-X 100 was added to control wells. To 
determine spontaneous lysis, target cells were incubated without CTLs. Supernatants 
were collected and read by an Isomedic -counter (ICN Biomedicals, Huntsville, AL). 
The percentage of 
51
Cr release was calculated by [(experimental 
51
Cr release-spontaneous 
51
Cr release)/(maximum 
51
Cr release-spontaneous 
51
Cr release)] x100. For in vivo CTL 
assay, recipient HHDII mice were left uninfected or challenged with 10
2
PFU of WNV-
NY a week before adoptive transfer of target cells. For target cells, naïve HHDII 
splenocytes were stained with 2M of PKH26 (Sigma, St. Louis, MO) and incubated 
with 1M of SVG9 or control peptide for 1 hour at 37C. After washing, SVG9- or 
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control peptide-pulsed cells were labeled with 1M or 50nM CFSE, respectively. Equal 
numbers of SVG9- and control peptide-pulsed cells were mixed in HBSS and 2x10
7
 total 
labeled target cells were transferred intravenously into the recipient mice. 6 hours later, 
spleen cells were harvested, fixed with PFA, and evaluated by flow cytometry. Target 
cells were distinguished from recipient cells based on PKH26 staining and from one 
another based on CFSE labeling. Gating on PKH26
+
 cells, the percentage of killing was 
calculated as follows: [1-(rnaive/rinfected)] x100, where r=%CFSE
low
 cells/%CFSE
hi
 cells. 
 
8. Single Chain Trimer (SCT) DNA Constructs  
The SVG9/HLA-A2*0201 SCT consists of the leader sequence of 2m followed 
by the SVGGVFTSV sequence, then a linker of 15 residues (G4S)3, and the mature 
human 2m sequence. The 2m was followed by the second linker of 20 residues (G4S)4 
and the chimeric HLA-A*0201 sequence of which the 3 domain was replaced by that of 
H-2K
b
. To generate SVG9/HLA-A2 SCTs, OVA.hB2m.HLA-A2 in an expression vector 
pIRESneo was used as a template. First, nucleotide oligos encoding SVG9 peptide 
flanked by restriction enzyme sites, Age1 and Nhe1 were designed in order to replace the 
existing OVA peptide; 5’-
CCGGTTTGTATGCTAGCGTGGGCGGCGTGTTTACCAGCGTGGGAGGAGGTG-3’ 
and 5’-
CTAGCACCTCCTCCCACGCTGGTAAACACGCCGCCCACGCTAGCATACAAA-3’. 
Oligos were annealed to form a double strand and inserted into the vector cut with Age1 
and Nhe1, which generated a pIRESneo.SVG9/HLA-A2 SCT with 3 domain of A2. 
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Next, to swap the 3 domain with H-2Kb, the plasmid was cut with BamH1 which 
resulted in the whole heavy chain excised from the plasmid. The fragment encoding 
A2/Kb 3 was prepared from pCR2.1topo.CMV. chimeric SCT (a kind gift from Dr. 
Beatriz Carreno, Washington University in St. Louis) and ligated into the vector, which 
generated pIRESneo.SVG9/A2/K
b
 3 chimeric SCT. The correct sequence was 
confirmed by DNA sequencing using BigDye3.1 (Washington University in St. Louis). 
For a control SCT, the SVG9 sequence was replaced with the mammoglobin A epitope, 
LIYDSSLCDL, sequence using similar cloning methods. To express a helper epitope, the 
Pan HLA-DR reactive epitope (PADRE) sequence (AKFVAAWTLKAAA) flanked by 
ATG and TAA was inserted before the leader sequence. For immunization, DNA was 
prepared using Plasmid Maxi Prep kit (Qiagen, Valencia, CA) according to the 
manufacturer's instructions 
 
9. DNA Immunization  
DNA-coated gold particle-mediated DNA vaccination was performed using a 
helium-driven gene gun (Bio-Rad, Hercules, CA). DNA-coated gold particles (diameter, 
1m) and cartridges were prepared according to the manufacturer’s instructions so that 
each cartridge contained 1g of DNA. The DNA-coated gold particles were delivered to 
the shaved abdomen of mice with a discharge pressure of 200 psi. Mice were immunized 
with 4g of DNA three times at 3 day intervals.  
 
10. IFN ELISpot assay 
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Spleens were harvested from mice 5 days after the last DNA immunization. After 
RBC lysis, single cell suspensions were incubated with 1g/mL SVG9 or control 
peptides in a PVDF filter plate (Millipore, Billerica, MA) pre-coated with 15g/mL of 
anti-IFN capture antibody (AN18, Mabtech Inc, Cincinnati, OH). After overnight 
stimulation, cells were removed and the plate was incubated with biotinylated anti-IFN 
detection antibody (R4-6A2) and subsequently with streptavidin-ALP. Then spots were 
developed by adding substrate solution (BCIP/NBT) and counted with an automated 
ELISpot reader (CTL, Shaker Heights, OH). 
 
11. Detection of WNV-specific Antibodies in Serum 
WNV-specific antibody titer was measured by ELISA. Serum was collected and 
added to the 96 well plates pre-absorbed with purified recombinant WNV E protein (5 
g/mL). After wash with washing buffer, PBS containing 0.05% Tween-20 (Sigma), 
plates were incubated with primary (biotinylated anti-mouse IgG or IgM, Sigma) and, 
subsequently with streptavidin-HPR for 1 hour. Then color was developed by adding 
TMB substrate (eBiosciences) and the reaction was stopped with 2N sulfuric acid. Plates 
were read on a plate reader (Bio-Rad) at 450nm. Endpoint titers were determined using 
GraphPad Prism 5. 
 
12. Quantification of Viral Burden  
For analysis of virus, brains were recovered after cardiac perfusion with PBS, 
homogenized, and titrated for virus by a plaque assay using BHK21 cells [76]. 10-fold 
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dilutions of a tissue homogenate were prepared, and 150 L aliquots were inoculated 
onto BHK21 cell monolayers that were prepared overnight. After a 1-2 hour incubation 
period, the monolayers were covered with a medium containing 1% agar and incubated 
for 3 days. The cells were fixed with 10% formaldehyde and stained with 1% crystal 
violet after agarose plugs were removed. Virus concentrations were determined as PFU/g. 
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Chapter 2.1 
Identification of the immunodominant WNV CD8
+
 T cell epitope 
 
Results 
Identification of an immunodominant peptide in HLA-A2 transgenic mice 
To identify WNV-derived peptides presented by HLA-A2 class I MHC molecules 
after infection, members of our group previously eluted peptides from affinity-purified 
HLA-A2 molecules isolated from uninfected or infected HeLa cells [74]. Comparative 
analyses using HPLC and tandem mass spectrometry (MS/MS) identified six virus-
derived peptides binding to HLA-A2 (Table 1). When tested in reactivation assays using 
CD8
+
 T cells from infected individuals, the WNV E-derived peptide (SVG9) was 
immunodominant. To develop the mouse model of WNV infection to study SCT vaccines, 
I determined whether these findings could be replicated in the HLA-A2 transgenic 
(HHDII) mouse model of WNV infection by comparing CD8
+
 T cell responses to these 
six WNV peptides.  
To assess the T cell responses against the six WNV peptides, HHDII mice were 
infected with 10
2
 PFU of a North American isolate of WNV (strain New York 1999 
(WNV-NY)). At 7 days after infection, splenocytes were harvested and stimulated ex vivo 
with each peptide for 4 hours and then stained for levels of intracellular IFN. Only the 
SVG9 peptide induced a strong IFN response in CD8+ T cells from infected mice (Fig. 
1A). On average, ~ 3% of CD8
+
 T cells produced IFN after restimulation with the SVG9 
peptide, whereas a much smaller percentage of CD8
+
 T cells produced IFN in response 
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to other peptides. Consistent with this finding, staining with SVG9 peptide/HLA-A2 
tetramers confirmed the presence of SVG9-specific CD8
+ 
T cells in infected spleens (Fig. 
1B). Thus, of the six viral peptides bound to HLA-A2, the SVG9 peptide is 
immunodominant in HHDII mice, results that parallel what was observed in infected 
humans [74]. This concordance supports the relevance of using the HLA-A2 transgenic 
mouse model to test vaccine efficacy for protection against WNV. Importantly, the SVG9 
(SVGGVFTSV) sequence is completely conserved in most contemporary and historical 
WNV isolates available in the NCBI database, including WNV-KUN, Egypt 101, the 
original Uganda 1937 lineage 2 isolate, and all Western Hemisphere strains that have 
been sequenced to date. Thus, this epitope is an excellent candidate to develop a CD8
+
 T 
cell-based WNV vaccine for HLA-A2 individuals. Thus, the immunodominant SVG9 
peptide was chosen to be incorporated into a SCT as a DNA vaccine hereafter. 
 
Epitope expression after WNV infection 
The high immunodominance of the SVG9 peptide suggests that it might be 
expressed at high levels on virus-infected cells. The six viral peptides listed in Table І, 
including the immunodominant SVG9 peptide, had been isolated from HLA-A2/peptide 
complexes secreted by WNV infected human HeLa tumor cells which had previously 
been transfected with a soluble HLA-A2 molecule. Thus it may not exactly recapitulate 
the actual antigen presentation that follows natural infection. I monitored actual antigen 
presentation of viral epitopes on the cell surface after infection using a novel TCR-mimic 
monoclonal antibody. TCR-mimic mAbs are specific for peptide/HLA-A2 complexes and 
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were generated by immunization of C57BL/6 mice with tetramers of peptide/HLA-A2 
[77, 78]. Three TCR-mimic mAbs with different specificities, RL15A, RL14C, and 
RL26A were used in this study. RL15A recognizes the SVG9/HLA-A2, RL14C the 
SLF9/HLA-A2, and RL26A the YTM9/HLA-A2 complex.  
HeLa or HeLa A2 cells that had been transfected with HLA-A2 were infected in 
vitro with WNV for 48 hours and stained with TCR-mimic mAbs. As a positive control, 
uninfected HeLa A2 were pulsed with each peptide for 4 hours prior to staining; as 
expected, the TCR-mimic mAbs bound to peptide-pulsed uninfected HeLa A2 cells but 
not to uninfected HeLa A2 cells or uninfected or infected HeLa cells (Fig. 2A). The 
degree of virus infection was confirmed using an anti-WNV envelope (E) protein 
antibody, E24 (Fig. 2B). All of the three SVG9/, SLF9/, and YTM9/HLA-A2 complexes 
were detected on the cell surface of infected HeLa A2 cells at high levels, but not on 
uninfected cells (Fig. 2B).  
I then decided to monitor the epitope presentation in a more physiologically 
relevant cell type, human dendritic cells (DCs) from HLA-A2 positive individuals. 
Human DCs are professional antigen presenting cells and known to likely be a primary 
cell type infected by WNV in vivo [79, 80]. Human DCs derived from the peripheral 
blood mononuclear cells of HLA-A2 positive individuals were cultured with GM-CSF 
and IL-4 and, at day 7 of the culture, infected in vitro with WNV for 48 hours and stained 
with TCR-mimic mAbs, RL15A and RL14C. As a positive control, uninfected DCs were 
pulsed with each peptide prior to staining. Consistent with the result from the experiment 
with HeLa cells, both SVG9/ and SLF9/HLA-A2 complexes were detected at high levels 
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on the cell surface of infected DCs, but not on uninfected cells (Fig. 3). Therefore, I 
confirmed that the immunodominant epitope SVG9 as well as the non-immunodominant 
epitopes are processed and presented in the context of HLA-A2 on the surface of antigen-
presenting cells after virus infection. Interestingly, I noticed that after infection the 
surface expression of SLF9/HLA-A2 is consistently higher than that of SVG9/HLA-A2 
in both HeLa A2 and human DCs, although SVG9 is more immunodominant than SLF9. 
Thus my data suggest that the level of epitope presentation on the APC alone does not 
explain immunodominance. 
 
TAP-dependency of viral antigen presentation 
To bind MHC I, a peptide should meet certain criteria; 8-10 amino acids in length 
and a hydrophobic or basic amino acid at its C-terminus [9]. The initial processing of the 
MHCI epitopes occurs in the cytosol by the proteasome after which peptides of 10-20 
amino acids are transported into the ER by TAP. Within the ER further trimming by the 
aminopeptidase (ERAAP) can occur prior to stable MHC I/peptide complex formation 
and subsequent ER exit to the plasma membrane. The relative importance of cytosolic 
processing can thus be determined by assessing TAP dependency of presentation of the 
epitope to T cells. Numerous epitopes detected by CD8
+
 T cells have been investigated 
and most have been found to be TAP-dependent suggesting their dependency on 
proteasomal processing. Regarding the importance of ER proteolysis for MHC I binding 
peptides, the processing and MHC binding of signal peptides is particularly relevant. A 
historical study first showed that in TAP deficient cells MHC I molecules are 
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predominantly loaded with signal peptides [81].  This finding implied that cleavage of 
signal peptides by signal peptidases, ERAAP and possibly other ER proteases is 
sufficient to generate MHC I binding peptides without access to the cytosol and 
proteasomes. However, it is noteworthy that there are exceptions to this conclusion. For 
example, the qdm signal peptide that binds to the mouse class Ib molecule Qa-1
b
 was 
found to be TAP-dependent, suggesting its proteasomal processing [82]. The model 
system we have developed in collaboration with the Diamond, Hildebrand, and Weidanz 
labs provides unique approaches to probe the host vs. viral proteases as well as the 
intracellular location of processing events that generate an immunodominant CD8
+
 T cell 
epitope during viral infection. 
Flaviviruses including WNV enter target cells by receptor-mediated endocytosis 
and then traffic to early endosomes, where the acidic environment induces fusion 
between the virus and the host membrane resulting in RNA genome release [83, 84]. 
Replication occurs on the host cell ER membrane where a replication complex, which 
consists of viral RNA, viral proteins, and possibly host cell factors, is assembled. 
Translation of viral RNA is followed by processing of the resulting polyprotein by host 
and virus-encoded proteases. Immature, noninfectious virions assemble within the ER 
and move through the host secretory pathway, where virion maturation occurs. Mature 
infectious particles are then released by exocytosis into the extracellular medium. WNV 
RNA is translated as a single polyprotein in the ER membrane, which is processed into 
ten viral mature proteins by viral and cellular proteases. Fig. 4 schematically illustrates 
the cleavage sites and topology of structural and nonstructural (NS) proteins at the ER 
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membrane. While host signal peptidase is responsible for cleavages between C/preM, 
preM/E, E/NS1, and within NS4b, a virus-encoded serine protease is responsible for 
cleavages between NS2a/2b, NS2b/NS3, NS3/NS4a, and NS4b/NS5 junctions. The viral 
envelope protein from which the SVG9 peptide derives, as well as the part of NS4b that 
includes the SLF9 epitope, is predicted to reside in the ER lumen, while NS3 including 
the YTM9 epitope is predicted to reside in the cytosol. 
The proteases that generate these aforementioned WNV epitopes are not known, 
but their identity is intriguing especially for the ones processing the SVG9 
immunodominant peptide. As previously noted, my data show that the SVG9 peptide is 
displayed at a high level at the cell surface after in vitro WNV infection of DCs 
suggesting efficient processing and loading of the SVG9 epitope into HLA-A2 molecules. 
Yet the WNV sequence including the SVG9 resides inside the ER. Thus we considered it 
of interest to examine the TAP-dependency of the antigen presentation of the SVG9 
epitope in comparison with the presentation of the SLF9 and YTM9 WNV epitopes. TAP-
dependency was determined by overexpressing the TAP inhibitor ICP47 (an HSV 
immune evasion protein) in HLA-A2
+
 cells prior to WNV infection. HLA-A2/peptide 
complexes were then enumerated by flow cytometry using TCR mimic mAbs. More 
specifically, HeLa or HeLa A2 cells expressing ICP47 were generated by transduction of 
a retrovirus encoding ICP47 and selection with antibiotics. As a control for ICP47 
blocking of TAP, an irrelevant HLA-A2 epitope (tumor peptide GVL) was expressed with 
an ubiquitin moiety and its HLA-A2 restricted expression was determined with a specific 
TCR mimic mAb (Fig. 5A). With ICP47 expressed, all of the three SVG9/, SLF9/, and 
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YTM9/HLA-A2 complexes were not presented at the cell surface after WNV infection 
(Fig. 5B). It was not because ICP47 affected MHC I expression itself, since total HLA-
A2 expression at the cell surface was not affected by ICP47 expression (Fig. 5C). This 
finding is consistent with published reports that HLA-A2 surface expression is largely 
TAP-independent.  
In summary data in this section indicate that antigen presentation of all three 
HLA-A2 restricted WNV epitopes examined here depends on TAP function. It is 
intriguing that TAP is required for the presentation of SVG9 and SLF9 WNV peptides 
which reside in the ER. Our findings suggest that these peptides are likely transported 
back to cytosol, processed by proteasomes and re-transported to the ER via TAP for 
binding to MHC I molecules. Host signal peptidases in the ER seem not to be able to 
process these peptides, rather viral proteases and/or proteasomes in the cytosol may be 
required. A mechanism for the efficient retro-transport of peptides from the ER is 
unknown and unexpected, but TAP functions only to introduce peptides into the ER. 
Alternatively, one might speculate that the SVG9 and SLF9 peptides are processed in 
post-ER endosomal compartments similar to mechanisms implicated in cross-
presentation of certain CD8
+
 T cell epitopes using in vitro assays. However, if post-ER 
processing is implicated, it remains unclear where HLA-A2 loading would occur in a 
manner efficient enough to achieve high levels of surface HLA-A2/SVG9 expression 
after WNV infection. In any case the application of the TCR mimic mAbs and mAbs 
from the Diamond lab to the WNV E protein have the ability to define the precise 
location of processing and HLA-A2 loading of the SVG9 immunodominant WNV 
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peptide.  
 
Cytotoxic T cells specific for the immunodominant epitope mediate partial protection 
against infection 
It was determined whether functional cytolytic CD8
+
 T cells specific for the 
immunodominant epitope, SVG9, are induced during viral infection and the CTLs 
contribute to control infection. First, cytolytic activity of CD8
+
 T cells was tested in vitro. 
For in vitro killing assays, bulk CD8
+
 T cells were generated from WNV-Kunjin (WNV-
KUN) immune spleen cells from HHDII mice after in vitro restimulation with SVG9 
peptide. We used WNV-KUN because the mortality rate with WNV-NY approached 
100% within 10 days of infection in the HHDII mice and so we were not able to obtain T 
cells to culture. WNV-KUN is a related lineage I WNV strain with reduced virulence in 
mice and humans and has 97.6% sequence identity with WNV-NY 1999, including 100% 
identity of the SVG9 peptide. In 
51
Cr-release assays, bulk CD8
+
 T cells from WNV-KUN 
immune mice lysed SVG9 peptide-loaded target cells as well as WNV-KUN infected 
cells (Fig. 6A). When these CD8
+
 T cells were incubated with target cells pulsed with 
SVG9 peptide in the presence of TCR-mimic antibody, RL15A or RL14C, RL15A 
completely blocked killing whereas RL14C which has the same IgG1 isotype did not 
alter killing (Fig. 6B). This indicates that SVG9-specific CD8
+
 T cells are cytotoxic. The 
cytotoxic activity was confirmed in vivo. A 1:1 mixture of differentially CFSE-labeled 
naïve syngeneic splenocytes pre-loaded with SVG9 or an irrelevant peptide was 
adoptively transferred into naïve HHDII mice or mice infected with WNV. Six hours later 
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the splenocytes were harvested and analyzed by flow cytometry for levels of CFSE 
expression. In naïve recipient mice, the 1:1 ratio of SVG9-loaded targets and irrelevant 
peptide-loaded targets remained the same (Fig. 6C). However, in infected mice, 58% of 
the SVG9-loaded targets were eliminated, but irrelevant peptide-loaded targets were not, 
indicating SVG9-specific killing of targets by T cells in vivo. Thus, during WNV 
infection, SVG9-specific CD8
+
 T cells are generated and lyse virus infected cells.   
Previous studies have established that CD8
+
 T cells contribute to viral clearance 
of WNV infected mice. Mice lacking CD8
+
 T cells or class I MHC developed higher 
central nervous system viral burdens and increased mortality rates after infection [73, 85]. 
Based on these findings, I assessed whether SVG9-specific CD8
+
 T cells could control 
WNV infection in vivo. Initially, an adoptive transfer experiment of SVG9-specific CD8
+
 
T cells into WNV infected mice was performed. Mice that received naïve CD8
+
 T cells 
had a 100% mortality rate within 10 days of infection (Fig. 7). In contrast, mice that 
received SVG9-restimulated CD8
+
 T cells exhibited a 40% survival rate (p<0.0005, n 
=10-11). Thus, enhanced CD8
+
 T cell responses specific for an immunodominant epitope 
SVG9 can provide protection against lethal WNV infection in vivo.  
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Figure Legends 
 
Table 1. Six identified WNV-derived peptides bound to HLA-A*0201 
Data was adapted from the previous publication by McMurtrey et al. [74]. NS, non-
structural protein, Env, envelope protein. IC50 is the concentration of the peptide that is 
required for 50% inhibition of the reference peptide binding. 
 
Figure 1. Identification of an immunodominant WNV epitope bound to HLA-A2 in 
HHDII mice 
HHDII mice were infected with 10
2
PFU of WNV, and 7 days later spleen cells were 
harvested. (A) Cells were stimulated in vitro with peptides for 4 hours in the presence of 
golgi-blocking agent. Then cells were stained for CD8 and intracellular IFN. The 
percentages of IFN+ CD8+ T cells after each peptide stimulation (x-axis) from infected 
() or naïve (∆) mice are shown. *, p<0.05 (unpaired t test). (B) Cells were stimulated in 
vitro with SVG9 peptide for 7 days, and stained with anti-CD8 mAb and SVG9/HLA-
A*0201 or control tetramers. Cells were gated on PI negative events. Numbers indicate 
the percentage of cells in each quadrant of total cells. 
 
Figure 2. Presentation of viral epitope/HLA-A2 complexes at the HeLa cell surface 
after WNV infection  
(A) HeLa or HeLa A2 cells were incubated with SVG9, SLF9, or YTM9 peptide for 4 
hours and stained with TCRm Ab, RL14C, RL15A, or RL26A. In each panel, shaded 
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histograms show staining of HeLa cells pulsed with each peptide and solid or dotted line 
shows HeLa A2 cells pulsed with an indicated or irrelevant peptide, respectively. (B) 
HeLa [86] or HeLa A2 (lower) cells were infected with WNV at a MOI of 1. 48 hours 
later, cells were stained with anti-WNV E24 or TCR mimic mAb. Shaded histograms 
show staining of uninfected cells and solid lines show infected cells.  
 
Figure 3. Presentation of viral epitopes, SVG9 and SLF9, at the human DC surface 
after WNV infection  
Primary dendritic cells derived from HLA-A2 positive PBMC were infected with WNV 
at a MOI of 1 for 48 hours. (A) Cells were stained with anti-WNV E24 (solid line) or 
isotype control mAb (dotted line). Shaded histogram, uninfected cells. (B) Uninfected 
(left) or infected [87] DCs were stained with RL14C (SLF9) [86] or RL15A (SVG9) 
(lower). Numbers indicate the percentages of TCRm positive cells.  
 
Figure 4. Schematic illustration of a WNV polyprotein expressed at the ER 
membrane 
The cleavage sites and topology of structural (in green) and nonstructural (NS) (in red) 
proteins at the endoplasmic reticulum (ER) membrane are illustrated schematically. The 
cleavage sites by host signalases or viral serine proteases were indicated with black or 
blue arrows, respectively. Approximate locations of the HLA-A2 binding epitopes in the 
viral polyprotein were indicated as yellow. C, capsid protein; E, envelope; preM, pre-
membrane; NS, nonstructural protein. 
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Figure 5. Presentation of viral epitopes at the cell surface is dependent on TAP 
function. 
(A) and (B) HeLa A2 cells expressing GVL peptide (solid line) or GVL and ICP47 
(dotted line) were infected with WNV at a MOI of 1 for 48 hours. Cells were stained with 
the indicated TCR mimic mAb. (A) Shaded histograms show staining of HeLa A2 cells 
without GVL peptide transfected. (B) Shaded histograms show staining of uninfected 
HeLa A2 cells expressing GVL and ICP47. (C) Infected cells were stained with anti-
HLA-A2 mAb, BB7.2 ; solid line, HeLa A2 cells expressing GVL peptide, dotted line, 
HeLa A2 cells expressing GVL and ICP47. A dashed line shows staining of uninfected 
HeLa A2 cells expressing GVL and ICP47 and a shaded histogram shows uninfected 
HeLa cells. 
 
Figure 6. WNV infection generates SVG9-specific CTLs 
(A) and (B) A 
51
Cr-release assay was performed with SVG9-specific CTLs as effectors. 
SVG9-sepcific CTLs were generated from spleen cells of mice that had been infected 
with WNV-KUN for a month. (A) (left) HeLa A2 targets were incubated with CTLs for 
4½ hours in the presence of 1 or 10M of SVG9 peptide. [87] HeLa or HeLa A2 cells 
infected with WNV-KUN were used as targets. (B) A 
51
Cr-release assay was performed 
in the presence of TCRm Ab. (C) An in vivo cytotoxic assay was performed. Histograms 
were gated on PKH26
+
 events (donor cells). The percentage of CFSE
hi
 or CFSE 
lo
 
population of PKH26
+
 cells is indicated in parentheses. All data are representative of at 
least two independent experiments with similar results.  
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Figure 7. Adoptively transferred SVG9-specific CTLs provide protection against 
lethal WNV infection 
Donor cells were obtained from HHDII mice that had been infected with 10
2
PFU of 
WNV. Cells were re-stimulated in vitro for 7 days with 0.1M of SVG9 peptide. CD8+ T 
cells were then isolated by negative selection and transferred into HHDII mice at day 1 
post-infection with 10
2
PFU of WNV (2x10
6
 CD8
+
 T cells per mouse). Survival was 
monitored over 28 days. **, p<0.0005 (log-rank test). The results were combined from 
two independent experiments (n=10-11 per group). 
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Table 1. Six identified WNV-derived peptides bound to HLA-A*0201 
Peptide Sequence Protein IC50(nM) 
RLD10 RLDDDGNFQL NS2b 847 
ATW9 ATWAENIQV NS5 780 
SVG9 SVGGVFTSV Env 247 
YTM9 YTMDGEYRL NS3 291 
SLT9 SLTSINVQA NS4b 503 
SLF9 SLFGQRIEV NS4b 204 
 
 
 
 
 
 
 
Table 1. Six identified WNV-derived peptides bound to HLA-A*0201 
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Figure 1. Identification of an immunodominant WNV epitope bound to HLA-A2 in 
HHDII mice 
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Figure 2. Presentation of viral epitope/HLA-A2 complexes at the HeLa cell surface 
after WNV infection 
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Figure 3. Presentation of viral epitopes, SVG9 and SLF9, at the human DC surface 
after WNV infection 
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Figure 4. Schematic illustration of a WNV polyprotein expressed at the ER 
membrane 
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Figure 5. Presentation of viral epitopes at the cell surface is dependent on TAP 
function. 
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Figure 6. WNV infection generates SVG9-specific CTLs 
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Figure 7. Adoptively transferred SVG9-specific CTLs provide protection against 
lethal WNV infection 
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Chapter 2.2 
SCT DNA vaccine-mediated protection against infection 
 
Results 
Generation of a SCT incorporating HLA-A*0201 and the SVG9 peptide 
To test the efficacy of SCTs as a DNA vaccine for viral infection, a SVG9/HLA-
A*0201 SCT (A2/SVG9 SCT) DNA construct was generated. The SCT construct 
consisted of a short leader sequence followed by the SVG9 peptide, a 15-amino acid 
linker, human 2m, a 20-amino acid linker, and a chimeric HLA-A2 heavy chain 
containing the 3 domain of Kb (Fig. 8A) and expressed from the pIRES expression 
vector. We generated a chimeric heavy chain of HLA-A2 instead of an intact heavy chain, 
because HHDII mice also express chimeric HLA-A2 molecules. As a control SCT DNA, 
a mammoglobin A epitope, which is a human breast tumor antigen known to bind HLA-
A2 [88], was inserted in place of the SVG9 sequence in the same plasmid. We also 
incorporated a CD4
+
 helper T cell epitope, PADRE (Pan MHCII reactive epitope), 
sequence into the construct to enhance CD8
+
 T cell responses. The pan CD4
+
 helper T 
cell epitope, PADRE (AKFVAAWTLKAA), is an engineered peptide that binds to 
multiple HLA-DR alleles, which also cross-reacts on mouse class II alleles [86]. 
Inclusion of this pan CD4 epitope in peptide or DNA vaccines has been shown to 
increase CD8
+
 T cell responses and vaccine efficacy in HHDII mice [41, 89-91]. 
To determine whether the A2/SVG9 SCTs are properly folded and expressed on 
the cell surface, HeLa cells were transfected with A2/SVG9 SCT DNA and stained with 
47 
 
anti-HLA-A2 antibody (BB7.2) or RL15A. A2/SVG9 complexes were detected on the 
cell surface by both antibodies (Fig. 8B), suggesting stable expression of the complexes 
with native folding. In addition, recognition of SCTs by T cells was examined in a 
cytotoxicity assay in vitro. A2/SVG9 SCT-expressing cells labeled with 
51
Cr were 
incubated with SVG9-specific CD8
+
 T cells for 4 hours and lysis was measured. SVG9-
specific CD8
+
 T cells lysed A2/SVG9 SCT-expressing target cells comparable to peptide-
pulsed target cells (Fig. 8C), confirming that SCTs are recognized by antigen-specific 
CD8
+
 T cells comparably to the native MHC/peptide complexes.  
 
DNA immunization of HLA-A2/SVG9 SCTs induces strong CD8
+
 T cell responses 
I then tested whether immunization with A2/SVG9 SCT DNA can elicit specific 
CD8
+
 T cell responses. A2/SVG9 or control SCT DNA plasmids were injected 
intradermally three times at three day intervals into the abdomen of naïve HHDII mice 
using a gene-gun approach [92]. Biolistic gene gun delivery involves adhering naked 
DNA to gold particles and shooting the particles through a high-pressured instrument. 
This system delivers DNA directly into skin and Langerhans cells in a highly efficient 
process. Gene gun immunization has been shown to induce a greater CD8
+
 T cell 
response as well as require less vaccine to achieve immunity [2, 93]. A short-interval 
repetitive schedule has been developed to lead to rapid and sustained induction of T cell 
responses upon gene-gun vaccination which was shown to mediate the regression of 
established tumors and prevent virus-induced morbidity [92]. According to previous 
studies, CD8
+
 T cell responses are at the peak around day 5 post-immunization by the 
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gene gun method. Thus, at day 5 after the last immunization, splenocytes were harvested 
and stained with SVG9/HLA-A2 tetramers or re-stimulated in vitro with SVG9 peptide to 
induce IFN production. Immunization with A2/SVG9 SCT DNA induced an average of 
27% of splenic CD8
+
 T cells to become antigen-specific as judged by tetramer positive 
reactivity (Fig. 9A) and production of IFN from about 20% of splenic CD8+ T cells after 
SVG9 peptide stimulation while control SCTs induced no responses (Fig. 9B). These 
findings demonstrate that SVG9 SCT DNA vaccination induces a robust SVG9-specific 
CD8
+
 T cell response in vivo.  
 
Protection against lethal WNV infection by SCT DNA vaccination 
Next, whether CD8
+
 T cell responses induced by vaccination with SCT DNA can 
provide mice protection against lethal WNV infection was examined. Naïve HHDII mice 
were immunized with A2/SVG9 or control SCT DNA plasmids and subsequently infected 
with 10
2
PFU of WNV-NY at day 5 after the last immunization. Mice immunized with 
control SCT DNA developed the expected CNS disease symptoms such as tremors and 
limb paralysis beginning at day 8 until death, which occured two to five days later (100% 
mortality rate) similar to naïve mice. In contrast, of mice immunized with A2/SVG9 SCT 
DNA, ~30% developed disease symptoms and 25% became moribund by day 10-13 after 
infection. The remainder of immunized mice never developed disease symptoms and 
were healthy for 60 days after infection (75% survival rate, Fig. 10). This result clearly 
establishes that T cell immunity induced by A2/SVG9 SCT DNA vaccination in the 
absence of a humoral response protects mice from lethal WNV infection.  
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Co-expression of CD4 helper epitope enhances protective efficacy of SCTs 
I assessed whether co-expression of the CD4
+
 T cell helper epitope, PADRE, is 
required for SCT vaccine efficacy. Naïve HHDII mice were immunized as above with 
DNA encoding A2/SVG9 SCT with PADRE or A2/SVG9 SCT without PADRE (Fig. 
11A). When T cell responses were compared at day 5 after the last immunization, 
interestingly, immunization of the A2/SVG9 SCT DNA with or without PADRE resulted 
in a comparable number of SVG9-specific T cells by IFN production (Fig. 11B). 
However, when survival rates upon lethal virus challenge were compared between two 
groups, co-expression of SCTs with PADRE was significantly more effective at 
conferring protective immunity (Fig. 11C; p<0.05, n =8-9) than SCTs without PADRE. 
 
SCT DNA immunization lowers viral burden in the brain 
WNV infection is thought to begin in Langerhans dendritic cells in the skin [67-
71, 79, 80]. Infected dendritic cells migrate to draining lymph nodes where replication 
occurs and infectious virus enters the circulation via the efferent lymphatic system and 
thoracic duct. Following viremia, virus spreads to visceral organs (e.g. liver, kidney, 
spleen) and the brain and spinal cord. CNS disease is suggested to be caused by neuronal 
degeneration induced directly by viral infection and/or by immune responses to the 
pathogen. To define the mechanism of disease protection, the viral burden in the brains of 
A2/SVG9 SCT and control SCT-immunized mice were compared on day 8, the time point 
at which infected HHDII mice became noticeably ill. Consistent with the clinical 
phenotype and decreased lethality, A2/SVG9 SCT-immunized mice had 100-fold lower 
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levels of WNV in the brain than control SCT-immunized mice (Fig. 12A). This effect was 
independent of humoral responses because the levels of anti-WNV E (envelope) IgG and 
IgM in the serum were comparable between the two groups (Fig. 12B). This finding was 
expected because the chemical stability of the SCT makes it unlikely that the SVG9 
epitope would be released to induce epitope-specific antibodies. Moreover, the SVG9 
epitope, which is located beyond domain III at residues 430-438 of the E protein, is not 
part of any known B cell epitopes for neutralizing antibody in mice or humans [94-96]. 
Thus, these results suggest that CD8 T cell responses induced by A2/SVG9 SCT 
immunization increased survival rate by limiting virus spread to the brain and/or by 
accelerating virus clearance.  
I also examined whether the SCT-immunized mice that survived viral infection 
developed memory CD8
+
 T cells and protective antibodies against the virus. Mice were 
vaccinated with A2/SVG9 SCT DNA, then infected with 10
2
PFU of WNV, and, at day 65, 
splenocytes and serum from the mice that survived were analyzed for the presence of 
SVG9/HLA-A2 tetramer positive cells and the ability to produce IFN upon restimulation 
with SVG9 peptide and for levels of specific antibodies against WNV E protein. About 
12% of CD8
+
 T cells in the spleens of immunized mice stained positive with SVG9-
specific tetramers and were CD44
hi
, consistent with a memory phenotype (Fig. 13A). 
Accordingly, ~11% of CD8
+
 T cells produced IFN after restimulation with the SVG9 
peptide (Fig. 13B). WNV E-specific IgG responses were detected in all A2/SVG9 SCT 
immunized mice, indicating non-sterilizing immunity and the induction of durable 
humoral responses after challenge (Fig. 13C).  
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Functional memory T cell responses develop after SCT DNA immunization 
So far, I have shown that primary responses by SCT DNA immunization protect 
mice against virus infection. Finally, whether DNA vaccination provides long-lasting 
protective immunity was addressed. Mice were vaccinated with A2/SVG9 SCT or control 
SCT DNA with PADRE as described above, rested for 45 days, and then challenged with 
10
2 
PFU of WNV. Before virus challenge, A2/SVG9 SCT-immunized mice had SVG9/A2 
tetramer positive, CD62L
lo
 and CD44
hi
 cells which consist of about 2% of CD8
+
 T cells 
in the spleen (Fig. 14A). Upon virus challenge, A2/SVG9 SCT-immunized mice 
developed greater CD8
+
 T cell responses than control mice. At day 7 after virus challenge, 
about 15% of splenic CD8
+
 T cells were SVG9/A2 tetramer positive and produced IFN 
in A2/SVG9 SCT-immunized mice, in contrast to about 2% in control mice (Fig. 14B). 
A2/SVG9 SCT DNA vaccination conferred 46% survival against lethal WNV infection 
(Fig. 14C; p<0.05, n =11-13), demonstrating functional memory T cell responses in 
vaccinated mice. Therefore, A2/SVG9 SCT DNA vaccination develops long-lasting CD8
+
 
T cell immunity that can confer protection against infection. 
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Figure Legends 
 
Figure 8. Expression of A2/SVG9 SCT and recognition by SVG9-specific T cells  
(A) Diagram of the SCT DNA encoding SVG9 or mammoglobin A (mamA) peptide 
/chimeric HLA-A2 complex. PADRE, Pan HLA-DR reactive epitope. SS, signal 
sequence. (B) Cell surface expression of A2/SVG9 SCT. HeLa cells were transfected 
with A2/SVG9 SCT DNA and stained with anti-HLA-A2 mAb (BB7.2, dotted line), 
RL15A (solid line), or isotype control Ab (shaded histogram). (C) Lysis of target cells 
expressing A2/SVG9 SCT. A2/SVG9 SCT-expressing HeLa cells were used as targets in 
a 
51
Cr-release assay with SVG9-specific CTLs. For controls, HeLa A2 cells or HeLa A2 
cells pulsed with SVG9 peptide were also used as targets.  
 
Figure 9. Induction of a strong CD8
+
 T cell response by HLA-A2/SVG9 SCT DNA 
immunization  
HHDII mice were immunized with A2/SVG9 or control SCT DNA three times at 3 day 
intervals. At 5 days after the last immunization, splenocytes were harvested. (A) 
Splenocytes from control (left) or A2/SVG9 SCT immunized mice [87] were stained with 
anti-CD8 mAb and SVG9/HLA-A*0201 tetramers. Numbers indicate the percentage of 
tetramer positive cells among CD8
+
 cells. Representative figures of the flow cytometry 
data. (B) Splenocytes from each group were stimulated in vitro with SVG9 or irrelevant 
peptide overnight and IFN secretion was measured by ELISPOT. Error bars indicate SE 
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of the experiment. The data presented are from one representative experiment of two 
performed independently with each group containing 4~5 mice.  
 
Figure 10. HLA-A2/SVG9 SCT DNA immunization provides mice protection 
against lethal WNV infection  
HHDII mice were immunized with SVG9 or control SCT DNA with PADRE. At 5 days 
after the last immunization, mice were infected with 10
2 
PFU of WNV. Mice were 
monitored over 60 days (n=11-12 per group). *, p<0.05 (log-rank test).  
 
Figure 11. Co-expression of a CD4
+
 helper T cell epitope enhances protective 
efficacy of SCTs 
(A) Diagram of a A2/SVG9 SCT DNA construct with or without an insertion of PADRE 
sequence. SS, signal sequence. (B) and (C) HHDII mice were immunized with A2/SVG9 
SCT with or without PADRE or control SCT DNA. (B) At 5 days after the last 
immunization, splenocytes were stimulated in vitro with 1 M of SVG9 or irrelevant 
peptide overnight. IFN secretion was measured by ELISPOT. Error bars indicate SD 
with n=5 mice per group. n.s., not significant (unpaired t test). (C) At 5 days after the last 
immunization, mice were infected with 10
2 
PFU of WNV and monitored over 30 days 
(n=8-9 per group). *, p<0.05 (unpaired t test) compared with A2/SVG9 SCT without 
PADRE. 
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Figure 12. HLA-A2/SVG9 SCT DNA immunization lowers viral burden in the brain 
but has no effect on humoral responses.  
Brain tissue and serum were collected at day 8 after viral challenge of HHDII mice that 
had been immunized with A2/SVG9 or control SCT DNA. (A) Viral burden in brain 
tissue was determined by a plaque assay. Naïve mice were used as a negative control. *, 
p<0.05 (unpaired t test). (B) The levels of anti-WNV IgG (left) and IgM [87] in the serum 
were measured by ELISA. n.s., not significant (unpaired t test).  
 
Figure 13. SCT DNA immunization induces non-sterilizing immunity 
Spleen and serum samples were taken from A2/SVG9 SCT DNA-vaccinated mice at day 
65 post-WNV infection. Naïve mice were used as a negative control. (A) Splenocytes 
were stained with anti-CD8, -CD44 mAb and SVG9/HLA-A*0201 tetramers. Percentage 
of tetramer
+
 CD44
hi
CD8
+
 T cells of four mice in each group was shown. Error bars 
indicate SD. (B) Splenocytes were stained for CD8 and intracellular IFN after 4 hour 
stimulation in vitro with SVG9 or irrelevant peptide in the presence of Golgi-blocking 
agent. Percentage of CD3
+
CD8
+
IFN+ cells is shown. Error bars indicate SD (C) WNV-
specific IgG titers in the serum were measured by ELISA. Data were expressed as 
reciprocal log endpoint titers after regression analysis. *, p<0.05 (unpaired t test). 
 
Figure 14. SCT DNA vaccine generates functional memory T cell immunity and 
provides long-term protection  
55 
 
HHDII mice were vaccinated with A2/SVG9 or control SCT DNA with PADRE as above 
and rested for 45 days before challenge with 10
2 
PFU of WNV. (A) At day 45 post-
immunization, splenocytes were stained with anti-CD8, -CD44, -CD62L mAb or 
SVG9/HLA-A*0201 tetramers. In all the panels, CD3 positive cells were gated and in the 
middle and right panels only CD8 positive cells were shown. (B) At day 7 after virus 
challenge, splenocytes were stained with SVG9/HLA-A*0201 tetramers and anti-CD8, -
CD44, or -CD62L mAb or CD8 and intracellular IFN after 4 hour stimulation in vitro 
with SVG9 or irrelevant peptide in the presence of Golgi-blocking agent. In all the panels, 
CD3 positive cells were gated and in the middle two columns only CD8 positive cells 
were shown. Numbers indicate the percentage of cells in each quadrant among CD3
+ 
CD8
+
 cells. Representative figures of the flow cytometry data. (C) After WNV challenge, 
mice were monitored over 25 days (n=11-13 per group). *, p<0.05 (log-rank test). 
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Figure 8. Expression of A2/SVG9 SCT and recognition by SVG9-specific T cells  
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Figure 9. Induction of a strong CD8
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Figure 10. HLA-A2/SVG9 SCT DNA immunization provides mice protection 
against lethal WNV infection 
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Figure 11. Co-expression of a CD4+ helper T cell epitope enhances protective 
efficacy of SCTs 
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Figure 12. HLA-A2/SVG9 SCT DNA immunization lowers viral burden in the brain 
but has no effect on humoral responses. 
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Figure 13. SCT DNA immunization induces non-sterilizing immunity 
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Figure 14. SCT DNA vaccine generates functional memory T cell immunity and 
provides long-term protection 
control A2 
SCT 
A2/SVG9 
SCT 
A2/SVG9 
SCT 
control A2 
SCT 
te
tr
a
m
er
 
CD8 CD62L CD44 
0.24 
1.67 
CD8 CD62L CD44 
14.21 
te
tr
a
m
er
 
1.99 
CD8 
2.54 
19.20 
IF
N
 
1 7
6.93 
63 
 
Discussion 
A DNA vaccine is an attractive approach to generate humoral and cellular 
immunity because plasmids are relatively safe, easy to produce, and readily amenable to 
technological improvements [2]. Of particular relevance for pathogen immunity, DNA 
vaccines induce CD8
+
 T cell immunity that may not be elicited by inactivated pathogen 
or protein subunit based vaccine platforms. DNA vaccines do not have the risks 
associated with production of live attenuated viral vaccines, especially for administration 
to the elderly or immunocompromised, the likely targets of diseases of many severe acute 
infections including WNV and seasonal influenza. Within the last few years several 
technical innovations in DNA vaccination have occurred including more effective 
delivery strategies, immune enhancements using adjuvants, and targeting to specific 
intracellular pathways. Even with these advances, a major hurdle for improving DNA 
vaccines is increasing immunogenicity. This issue is particularly relevant for larger 
animals and humans where the DNA platform has proven less effective than in mice. 
Here, we utilized a unique approach to improve CD8
+
 T cell responses by targeting an 
immunodominant WNV epitope to the class I MHC antigen presentation pathway with 
SCT based technology. 
Several properties of SCTs likely contribute to their effectiveness in eliciting a 
CD8
+
 T cell response. The expressed SCT polypeptide includes all three MHC class I 
components, peptide, 2m and heavy chain attached sequentially with flexible linkers 
[11]. The SCT platform appears readily applicable to different mouse and human 
MHCI/peptide complexes [24, 31]. The preassembled nature of SCTs allows them to 
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rapidly fold, exclude the binding of competitive peptides, and expediently transit to the 
cell surface. Furthermore, the linker controlled peptide occupancy renders the SCT stable 
at the cell surface. Once on the cell surface, SCTs are recognized by CD8
+
 T cells in a 
manner comparable to native class I/peptide complexes [11]. Thus, immunization with 
SCTs induces the stable display of specific class I/peptide complexes for a duration 
sufficient to elicit a robust CD8
+
 T cell response. Indeed, there are now several published 
examples of plasmids encoding SCTs that elicit robust CD8
+
 T cell responses in model 
systems and SCT based vaccines confer protection against tumor challenge in mice [30, 
31]. Although SCTs incorporating viral epitopes have been shown to elicit CD8
+
 T cells, 
prior to our study, no previous reports have documented the utility of SCT-based vaccines 
in conferring protection against lethal challenge by a pathogen. Application of SCTs to 
pathogen immunity is attractive given that CD8
+
 T cells detect unique pathogen-derived 
epitopes, whereas tumor-associated epitopes are typically over-expressed self-proteins. It 
is also notable that immune evasion mechanisms can mitigate CD8
+
 T cell responses to 
pathogens by mechanisms that include blocking antigen presentation. Indeed, commonly 
used viral immune evasion mechanisms prevent peptide generation by inhibiting 
proteasome function or peptide loading by inhibiting TAP function [97]. The 
preprocessed and preassembled nature of the SCT makes their expression impervious to 
these mechanisms of immune evasion [98].         
The ongoing discovery of pathogen-derived peptide epitopes presented by 
different HLA molecules will allow construction of tailored SCT based vaccines. The 
effectiveness of SCT vaccines may be related to the immunodominance of particular 
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CD8
+
 T cell epitopes. Mechanistically, immunodominance is believed to be affected by 
(i) peptide abundance as determined by the turnover rate of the donor protein and the 
peptide processing efficiency, (ii) peptide binding affinity to class I MHC molecules, and 
(iii) the CD8
+
 T cell repertoire, which is determined during thymic selection. Although 
six different WNV peptides were eluted from HLA-A2 molecules, the E derived peptide 
SVG9 was immunodominant in HLA-A2 transgenic mice and in humans. This 
concordance suggests that the SVG9 peptide is efficiently processed and presented by 
both mouse and human APCs. Taking advantage of TCR-mimic antibodies, I was able to 
show that high levels of SVG9/HLA-A2 complexes were displayed on the surface of 
mouse or human cells infected in vitro with WNV. Interestingly, comparably high levels 
of HLA-A2 bound by the SLF9 and YTM9 peptide were also displayed on the cell 
surface of WNV infected cells (see Fig. 3B and Fig. 4B), even though few if any SLF9- 
or YTM9-specific CD8
+
 T cells were detected in re-stimulation assays. Presentation of all 
the three epitopes at the cell surface was dependent on TAP, regardless of its location in 
the cells. Thus, the level of epitope presentation on the APC alone does not explain 
immunodominance. It is consistent with a previous report that the magnitude of the CD8
+
 
T cell response to different epitopes is only minimally affected by their abundance in 
infected cells [99]. After a threshold quantity of antigen has been presented, the 
magnitude of the T cell response is unaffected by increased presentation of antigen. We 
speculate the T cell repertoire must also contribute to the immunodominace of the SVG9 
peptide.  
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Plasmid DNA encoding a SCT with the SVG9 peptide elicited a robust CD8
+
 T 
cell response as determined by intracellular IFN production and protective immunity 
against WNV infection. Co-expression of a helper epitope with the SCT did not affect the 
level of SVG9-specific T cells, but was required for optimal protective immunity. This 
observation is consistent with the previous findings showing that CD4-deficiency did not 
affect the primary CD8
+
 T responses but did compromise the responses at later time 
points after WNV infection [100]. This study demonstrated that re-stimulation of WNV-
specific CD8
+
 T cells and the number of CD8
+
 T cells in the CNS of CD4-deficient mice 
were compromised only late during infection, suggesting that CD4
+
 T cells play a role in 
sustaining primary responses and the level of CD8
+
 T cells in the CNS. Also CD4-
deficiency resulted in increased lethality. The mechanism through which CD4
+
 T cells 
provide help to CD8
+
 T cells is as yet unclear. CD4
+
 T cells may secret cytokines to 
sustain or increase CD8
+
 T cell numbers. Also, it has been reported that whereas CD4
+
 T 
cell help does not modify the initial response of naïve CD8
+
 T cells, it appears to be 
fundamental for generation of efficient memory cells [101-103]. Thus the inclusion of the 
helper epitope in the SCT likely facilitates development of central and effector memory 
or the presence of memory T cells in tissues. Our results prove that the flexibility of the 
SCT platform can combine with other strategies to enhance DNA vaccine potency. Our 
studies also confirm the importance of CD8
+
 T cells in controlling WNV during primary 
infection [85, 104-106]. Indeed, the induction of WNV-specific CD8
+
 T cells was 
sufficient to control infection in the complete absence of humoral immunity. These 
findings also extend earlier studies in which adoptive transfer of bulk CD8
+
 T cells from 
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infected mice protected naïve mice from WNV challenge and immunization with a D
b
-
restricted immunodominant NS4b peptide limited WNV-induced disease and mortality 
[72, 73].  
Although SCT vaccines elicit antigen-specific CD8
+
 T cells, it is likely that their 
effectiveness can be enhanced once the immune response to DNA vaccination is better 
understood. For example, the identity of the critical cells expressing antigens after DNA 
vaccination remains controversial as well as the relative importance of direct versus 
cross-presentation for CD8
+
 T cell activation [2, 45, 48]. To realize the full potential of 
SCT vaccine approaches it will be necessary to define the precise cellular and molecular 
mechanism of antigen presentation after DNA plasmid vaccination. Then, expression of 
the SCT can be targeted to appropriate cell types to provide maximal CD8
+
 T responses. 
In summary, SCT-based DNA vaccines have the potential to induce pathogen-specific 
CD8
+
 T cell responses. Incorporation of an SCT vaccine with other classical approaches 
that elicit robust humoral immunity may provide a focused approach to stimulating both 
arms of the adaptive response and generating protective immunity against a range of 
infectious diseases. 
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Chapter 3 
H-2K
d
 SCT DNA vaccines and Listeria infection 
 
Introduction 
In the previous study using HLA-A*0201 SCTs in the mouse model of West Nile 
virus infection, I demonstrated for the first time that SCT DNA vaccination induces 
protective T cell immunity against virus infection. This suggested that the SCT platform 
can be incorporated into a composite vaccine targeting multiple aspects of immunity 
against viral infection and opened the possibility that SCT-based DNA vaccines may be 
applied to other infectious disease models. The HLA-A2 transgenic mouse model of 
WNV infection was unique in that the immunodominance of the SVG9 epitope is very 
strong. However, this immunodominance may partially be attributed to the fact that 
relatively few CD8
+
 T cells developed in HHDII mice due to impaired heterologous 
interactions of host mouse proteins with the chimeric HLA-A2 transgene [107]. Thus we 
next wanted to extend these findings in the more physiologic C57BL/6 model. Such an 
approach was made possible by a recent collaborative study between the Diamond, 
Hansen and Fremont labs as well as studies by the Nikolich-Žugich lab that defined 
immunodominant WNV epitopes presented by D
b
 and K
b
 molecules [72, 73]. 
Unexpectedly, however, construction of SCTs with these immunodominant WNV 
epitopes and mouse K
b
 or D
b
 was problematic (discussed in Chapter 4 and 5). Therefore 
as an alternate plan to test pathogen protection of SCT-based vaccines in a non-transgenic 
model, we chose to use the BALB/c infection model of Listeria monocytogenes. The 
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advantage of using the BALB/c Listeria model is that the immunodominant epitopes 
detected by CD8
+
 T cells are well documented and CD8
+
 T cells are known to play a 
prominent role in pathogen protection. In addition, the modest contribution of help seen 
in our SCT-based vaccine to WNV in the HHDII mice was unexpected, so we wanted to 
extend this observation to a model system where the role of help was well documented. 
Advantageously, the Unanue lab has considerable expertise using the BALB/c model to 
study Listeria immunity and we are grateful to Drs. Javier Carrero and Emil Unanue for 
their help with these experiments. 
Listeria monocytogenes is a gram positive intracellular bacterium that can cause 
human disease, listeriosis, particularly in immunocompromised individuals. L. 
monocytogenes infects a broad range of hosts and is often used to study the mammalian 
immune response to infection because it is easy to culture, safe to work with, and causes 
a highly predictable infection in mice [108, 109]. Mouse models of Listeria infection 
have been well established and provided several insights into the immune responses to 
bacterial infection [109]. Although innate immune cells are critical for control of early 
stages of L. monocytogenes infection, they are unable to eliminate bacteria from the 
mouse. L. monocytogenes infection elicits a robust T cell response that clears the 
pathogen from infected mice and provides long-lasting immunity while humoral 
immunity provides only a small contribution to protect mice. CD8
+
 T cells play a more 
substantial role than CD4
+
 T cells in conferring long term protective immunity 
particularly in the BALB/c mouse model [110, 111]. The BALB/c model has been 
informative in that immunodominant CD8
+
 T cell epitopes have been well characterized 
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[112-114]. Furthermore, in tetramer analyses the magnitude and kinetics of CD8
+
 T cell 
responses to the epitopes have been elegantly characterized [114, 115]. During primary 
infection, L. monocytogenes proliferates in vivo for 3 to 4 days following infection and is 
then cleared by the increasing T cell response within 7 to 8 days post infection. After re-
infection with L. monocytogenes, memory CD8
+
 T cell populations rapidly respond and 
clear bacteria from infected tissues. The MHC class I restricted L. monocytogenes 
epitopes are generated from proteins, many of which are also virulence factors, secreted 
into cytosol. Listeriolysin O, LLO, is one of the most antigenic of the proteins secreted by 
L. monocytogenes [116, 117]. In BALB/c infection, the epitope of LLO (residues 91-99) 
restricted by H-2K
d
 has been defined as the most immunodominant CD8
+
 T cell epitope 
[118].  
The ability to quickly and specifically eliminate recurring infections is a hallmark 
of immunological memory. Thus, the generation of quality memory CD8
+
 T cells is an 
appealing goal for vaccine design against a variety of infectious diseases. In the L. 
monocytogenes infection model, it has been well known that CD4
+
 T cell help promotes 
protective memory CD8
+
 T cell development [101-103, 119]. So we tested whether CD4
+
 
T cell help can improve the efficacy of SCT DNA vaccine by co-expressing CD4
+
 helper 
T cell epitopes with the SCT. For this purpose, we compared two known CD4
+
 helper T 
cell epitopes, a pan CD4
+
 T cell epitope and a well-known CD4
+
 T cell epitope of L. 
monocytogenes that binds to MHC class II I-A
d
, LLO 188-201. The pan CD4
+
 T cell 
epitope (PADRE, AKFVAAWTLKAA), as described in Chapter 2.2, is an engineered 
peptide that binds to multiple HLA-DR alleles, which also cross-reacts on mouse class II 
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alleles [86]. L. monocytogenes peptide LLO 188-201 (RWNEKYAQAYPNVS) has been 
reported to be the most immunodominant CD4
+
 T cell epitope binding to I-A
d
 in the 
BALB/c model of L. monocytogenes infection [113]. Regarding the specificity of CD4
+
 T 
cell help required for optimal generation and maintenance of memory CD8
+
 T cell 
responses, it has been proposed that both CD4
+
 and CD8
+
 T cells are required to be 
specific for the same antigen [120, 121]. However, the recently published data indicate 
that helper T cell function is not antigen specific and likely results through cytokines [119, 
122-125]. The discrepancy between the studies may result from using different 
experimental systems such as inflammatory or non-inflammatory and/or different 
precursor frequencies of antigen specific CD8
+
 T cells. Thus, our study not only 
examined the role of CD4
+
 T cell help in SCT-induced memory immune responses, but 
also compared L. monocytogenes-specific vs. -nonspecific CD4
+
 T cell epitopes for their 
ability to help protective CD8
+
 T cell responses induced by SCT-based DNA vaccines. 
Our vaccination approach was attractive conceptually because the CD4
+
 helper T cell 
epitopes were specifically targeted to the MHC class II antigen presentation pathway 
using an Ii (invariant chain) expression vector, whereas a CD8
+
 T cell epitope was 
specifically targeted to the MHC class I antigen presentation pathway using an SCT 
expression vector. 
I generated a H-2K
d
 SCT incorporating the LLO 91-99 epitope that is recognized 
by peptide-specific CD8
+
 T cells. DNA vaccination with plasmids encoding K
d
/LLO91-99 
SCTs by gene gun induced epitope-specific primary and memory CD8
+
 T cell responses 
in BALB/c mice and the vaccinated mice showed better control of bacteria upon lethal L. 
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monocytogenes infection. The SCT alone was able to develop functional memory CD8
+
 T 
cells and the presence of CD4
+
 T cell help, whether it is cognate or non-cognate, 
marginally enhanced memory CD8
+
 T cell responses. Therefore, our data suggest that a 
SCT-based DNA vaccine can elicit a potent antibacterial CD8
+
 T cell immunity and thus 
broaden the application of SCTs in pathogen diseases. 
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Materials and Methods 
1. Cell lines 
Transient transfection was performed on 293T human embryonic kidney cells 
using Lipofectamine 2000 (Invitrogen). LLO 91-99 specific, H-2K
d
-restricted T cell 
hybridoma, 206.15, was a generous gift from Dr. Emil Unanue at Washington University 
in St. Louis. The hybridoma was maintained in modified DMEM (Invitrogen) 
supplemented with 10% FBS (HyClone Laboratories, Logan, UT), 1.5mM L-glutamine, 
10mM HEPES, 1mM sodium pyruvate, 116mg/L L-arginine, 36mg/L L-asparagine 
(Sigma) and 100U/mL penicillin/streptomycin (Tissue Culture Support Center, 
Washington University School of Medicine, St. Louis, MO).  
 
2. SCT construct 
To generate H-2K
d
/LLO91-99 SCT, the H-2K
d
 SCT with HER2/Neu peptide in 
pcDNA3.1(-) expression vector was used as a template. Nucleotide oligos encoding LLO 
91-99 peptide, GYKDGNEYI, flanked by restriction enzyme sites, AgeI and NheI, were 
designed in order to replace the existing epitope sequence; 5’-
ccggtttgtatgctggctataaagatggcaacgaatatattggaggaggtg-3’ and 5’- 
ctagcacctcctccaatatattcgttgccatctttatagccagcatacaaa -3’. Oligos were annealed to form a 
double strand and inserted into the vector cut with AgeI and NheI.  
To express SCTs and CD4
+
 T cell helper epitopes simultaneously, the pIRES 
expression vector was used and to direct CD4
+
 T cell helper epitopes to the endosome the 
invariant chain (Ii) was exploited. The entire sequences encoding SCTs and Ii were 
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cloned from the original plasmids into the pIRES vector using extended PCR and ligation. 
Using two step overlapping PCR, the CLIP sequence of Ii was replaced with helper 
epitopes; PADRE (pan T helper epitope), AKFVAAWTLKAAA, or LLO189-201, 
WNEKYAQAYPNV. For immunization, DNA was prepared using the Plasmid Maxi Prep 
kit (Qiagen) according to the manufacturer's instructions. 
 
3. Hybridoma activation assay and ELISA 
Activation of the T hybridoma was assessed by measuring IL-2 secreted upon 
activation. T hybridoma cells were co-cultured with 293T cells transiently transfected 
with SCTs overnight at 37°C. After incubation, the culture supernatants were taken and 
the amount of IL-2 was measured by ELISA. The supernatant was added to a 96 well 
plate pre-coated with anti-IL-2 capture antibody, JES6-1A12 (BioLegend, San Diego, 
CA), overnight at 4°C and blocked with carbonate/bicarbonate coating buffer. After wash 
with washing buffer, PBS containing 0.05% Tween-20 (Sigma), biotin- anti-IL-2 
detection antibody, JES6-5H4 (BioLegend), was added to the plates followed by 
incubation with avidin-HRP (eBiosciences). Color was developed by adding TMB 
substrate (eBiosciences) and the reaction was stopped with 2N sulfuric acid. Plates were 
read on a plate reader (Bio-Rad) at 450nm.  
 
4. L. monocytogenes and mouse infection 
BALB/c mice were purchased from NCI, maintained under specific pathogen-free 
conditions at the Washington University School of Medicine and were handled in 
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accordance with the guidelines set by the Division of Comparative Medicine of 
Washington University. Listeria monocytogenes strain EGD was stored as frozen glycerol 
stocks at −80°C. All mice were infected intraperitoneally with various doses of L. 
monocytogenes EGD strain in pyrogen-free saline. For primary infection, 10
3
 L. 
monocytogenes were injected. Re-immunization was performed with either 2 x 10
5
 or 5 x 
10
4
 L. monocytogenes. 
 
5. Flow cytometry 
Cell culture supernatant containing SF.1-1.1.1, monoclonal anti-H-2K
d 
antibody, 
was used to stain K
d
/LLO91-99 SCT-expressing cells. The following mAbs were purchased 
from eBiosciences: anti-CD8 (53-6.7)-FITC, CD4 (GK1.5)-FITC, CD44 (IM7)-APC, 
CD62L (MEL-14)-APC, CD3 (145-2C11)-APC or -PE, IL-2 (JES6-5H4)-PE, IFN 
(XMG1.2)-PE, rat IgG1 isotype control-PE, and PE-conjugated goat anti-mouse Ig. PE-
conjugated K
d
/LLO91-99 and control tetramer were obtained from the National Institute of 
Allergy and Infectious Diseases tetramer facility (Emory University, Atlanta, GA). For 
intracellular cytokine staining, splenocytes were stimulated in vitro with peptide at 
0.1g/mL in the presence of GolgiPlug (BD Biosciences, San Jose, CA) for 4 hours at 
37C. Cells were washed and incubated with FcR blocking antibody (2.4G2, 
eBiosciences), stained with anti-CD8, CD4, CD3, and/or CD62L mAb, and fixed with 
1% paraformaldehyde (PFA). After washing twice with buffer containing 0.1% saponin, 
cells were stained with anti-IFN, IL-2 mAb, or isotype control antibody. For tetramer 
staining, cells were stained with tetramers for 30 min at 4C, and subsequently anti-
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CD8 or CD44 mAb was added for an additional 20 min at 4C. Propidium iodide (PI) 
was added shortly before flow cytometry to gate out dead cells. Cells were acquired on 
FACSCalibur and data were analyzed with FlowJo software (Tree Star). 
 
6. IFN ELISpot assay 
Spleens were harvested from mice 5 days after the last DNA immunization. After 
RBC lysis, single cell suspensions were incubated with 1g/mL LLO 91-99 or control 
peptides in a PVDF filter plate (Millipore, Billerica, MA) pre-coated with 15g/mL of 
anti-IFN capture antibody (AN18, Mabtech Inc, Cincinnati, OH). After overnight 
stimulation, cells were removed and the plate was incubated with biotinylated anti-IFN 
detection antibody (R4-6A2) and subsequently with streptavidin-ALP. Then spots were 
developed by adding substrate solution (BCIP/NBT) and counted with an automated 
ELISpot reader (CTL, Shaker Heights, OH). 
 
7. Colony count 
L. monocytogenes numbers in the spleen and liver were estimated by determining 
colony forming units (CFU) from tissue homogenates on brain heart infusion agar (BHI) 
plates using standard procedures. Briefly, a spleen or liver was homogenized in buffer 
containing PBS with 0.05% Triton X-100 (Sigma). Serially diluted tissue homogenates 
were plated onto BHI plates and incubated for 15-20 hours at 37°C. Colonies on each 
plate were counted. For all graphs, data were plotted using Prism software (Graphpad). A 
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Mann-Whitney unpaired test with two-tailed p-values and 95% confidence intervals was 
used for all statistical analyses. 
 
 
 
78 
 
Chapter 3.1 
H-2K
d
/LLO91-99 SCT mediated protection against L. monocytogenes infection 
 
Results 
H-2K
d
 SCTs incorporating LLO 91-99 epitope are recognized by peptide-specific CD8
+
 T 
cells 
An SCT construct, which consists of the leader sequence of 2m, GYKDGNEYI 
(LLO 91-99, L. monocytogenes immunodominant epitope), the first flexible linker of 15 
residues (G4S)3, the mature mouse 2m, the second flexible linker of 20 residues (G4S)4, 
and the heavy chain of H-2K
d
 was generated in the pcDNA3 expression vector. As a 
control, the plasmid encoding K
d
 SCTs with HER2/neu peptide, a breast cancer antigen, 
in the same vector was used. To check the expression at the cell surface, 293T cells were 
transiently transfected with plasmids encoding K
d
/LLO91-99 SCTs. SCTs were stained with 
the monoclonal antibody specific for folded K
d
, SF1-1.1.1, indicating they were 
expressed and folded properly on the cell surface after transfection (Fig. 15A). These K
d
/ 
LLO91-99 SCT-expressing cells were incubated with CD8
+
 T hybridomas cells specific for 
K
d
/LLO91-99 complexes for 24 hours to see whether SCTs can activate T cells. T 
hybridomas cells secreted IL-2 in response to K
d
/LLO91-99 SCTs but not to control K
d
 
SCTs (Fig. 15B). These results indicate the successful generation of K
d
/LLO91-99 SCTs 
that are recognized by and activate peptide-specific CD8
+
 T cells. 
 
DNA immunization with K
d
/ LLO91-99 SCTs induces specific CD8
+
 T cells 
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To test the ability of SCT to induce specific CD8
+
 T cells, BALB/c mice were 
immunized intradermally with plasmids encoding K
d
/LLO91-99 SCTs or control SCTs 
three times at three day intervals by gene gun. At day 5 after the last immunization, LLO 
91-99 specific CD8
+ 
T cells were detected in the spleen from mice immunized with 
K
d
/LLO91-99 SCTs using a tetramer assay (Fig. 16A). In ELISPOT, about the same 
percentage (~1%) of splenocytes produced IFN in response to in vitro peptide re-
stimulation, but none from mice immunized with control SCTs (Fig. 16B). Interestingly, I 
observed a similar or smaller percentage of K
d
/LLO91-99 tetramer positive CD8
+
 T cells in 
the spleens from mice infected with a sublethal dose of L. monocytogenes for 7 days (Fig. 
16A). Thus, this indicates that K
d
/LLO91-99 SCT DNA immunization induces an antigen-
specific CD8
+
 T cell response which is comparable to that induced by natural infection.  
 
Protection mediated by K
d
/LLO91-99 SCT DNA vaccine against L. monocytogenes 
infection  
How a SCT DNA vaccine influences the outcome of L. monocytogenes infection 
was next determined. After K
d
/LLO91-99  or control SCT DNA vaccination by gene gun as 
described above, mice were infected intraperitoneally with a lethal dose of L. 
monocytogenes (2x10
5
 of strain EGD) at 2 or 4 weeks. For controls to show natural 
immunity, groups of mice were not infected or were infected with a sublethal amount of L. 
monocytogenes (10
3
). Mice were monitored for growth of the L. monocytogenes in spleen 
and liver at 3 days after infection, since, during secondary infection, infected mice 
usually eliminate L. monocytogenes within 3-4 days [126, 127]. K
d
/LLO91-99 SCT DNA 
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vaccinated mice had one log-fold lower bacteria counts (CFU, colony forming units) than 
control SCT vaccinated mice in both spleen and liver (statistical significance, unpaired t 
test, P<0.05) whether mice were challenged with L. monocytogenes at 2 weeks or 4 
weeks after vaccination (Fig. 17). Control SCT DNA vaccinated mice had the same 
bacteria counts as untreated mice while mice immunized with a sublethal dose of L. 
monocytogenes showed similar or lower bacteria counts than K
d
/LLO91-99 SCT DNA 
vaccinated mice. This result demonstrates that K
d
/LLO91-99 SCT DNA vaccination can 
induce a protective immune response against lethal L. monocytogenes infection. 
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Figure Legends 
 
Figure 15. Expression and recognition of K
d
/ LLO91-99 SCTs by CD8
+
 T cells  
(A) Cell surface expression of K
d
/LLO91-99 SCTs. 293T cells were transfected with K
d
/ 
LLO91-99 SCT DNA and stained with anti-K
d
 mAb (SF1-1.1.1, solid line). A shaded 
histogram shows staining of untransfected cells. (B) Activation of hybridomas specific 
for LLO 91-99/K
d
 by K
d
/LLO91-99 SCT-expressing cells. Transfected 293T cells were 
incubated with T hybridomas at the ratios of 8:1, 4:1, or 1:1 for 24 hours and the amounts 
of IL-2 in the culture supernatant were measured by ELISA. For controls, P815 cells that 
express endogenous K
d
 were incubated with hybridomas with or without 1g/mL of LLO 
91-99 peptide.  
 
Figure 16. K
d
/ LLO91-99 SCTs DNA immunization induces peptide-specific CD8
+
 T 
cells 
Mice were immunized with K
d
/LLO91-99 or control K
d
 SCT DNA three times at 3 day 
intervals. At 5 days after the last immunization, splenocytes were harvested. (A) 
Splenocytes from control (left), K
d
/ LLO91-99 SCT (middle), or L. monocytogenes-
immunized mice [87] were stained with anti-CD8 mAb and LLO 91-99/K
d
 tetramers. 
Numbers indicate the percentage of tetramer positive cells among CD3
+
 CD8
+
 cells. 
Representative figures of the flow cytometry data. (B) Splenocytes from each group were 
stimulated in vitro with LLO 91-99 or irrelevant peptide overnight and IFN secretion 
was measured by ELISPOT. Error bars indicate SE of the experiment. The data presented 
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are from one representative experiment of two performed independently with each group 
containing 4~5 mice. 
 
Figure 17. A K
d
/LLO91-99 SCT DNA vaccine lowers bacterial burden in lethal L. 
monocytogenes infection 
Mice were immunizaed with K
d
/LLO91-99 or control K
d
 SCT DNA by gene gun as 
described above and infected intraperitoneally with 2x10
5
of L. monocytogenes at 2 [86] 
or 4 weeks (lower) post immunization. For controls, mice were infected with 10
3
 of L. 
monocytogenes or left uninfected. At 3 days after infection, spleens and livers were 
harvested and bacteria counts were determined by colony count. Error bars indicate SEM 
of the experiment. Data were expressed as log10 of colony forming units (CFU). n.s., not 
significant. *, p<0.05 (unpaired t test). 
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Chapter 3.2 
Role of cognate vs. non-cognate CD4
+
 T cell help for protection 
 
Results 
Memory CD8
+
 T cell responses after SCT DNA immunization 
Generation of functional memory responses is a critical issue for vaccines against 
infection. In the previous chapter, I showed that mice have protective immunity at 4 
weeks after SCT DNA immunization. But antigens may be still expressed at the time of 
bacteria challenge because it was reported that antigen expression was still detectable at 
10 weeks following intradermal DNA injection [128]. Therefore I examined whether 
memory CD8
+
 T cells are generated after DNA immunization of SCTs and their 
functionality at later time points. Mice were immunized with DNA encoding K
d
/LLO91-99 
or control SCTs as described above and rested for 5 months before L. monocytogenes 
challenge. 5 months after immunization, K
d
/LLO91-99 tetramer positive CD8
+
 T cells were 
present in the spleen of resting mice immunized with K
d
/LLO91-99 SCTs, and IFN 
production was detected after peptide stimulation in vitro (Fig. 18A and B). The CD8
+
 T 
cells had memory phenotypes, CD44
hi
 and CD62L
lo 
(Fig. 18A and not shown). These 
mice were infected with 5x10
4 
L. monocytogenes and 3 days later bacteria in the spleen 
and liver were counted. Mice vaccinated with K
d
/LLO91-99 SCTs had 10-fold less bacteria 
than mice immunized with control SCTs (Fig. 18C). This was a similar result to that from 
L. monocytogenes challenge at 2 or 4 weeks post-immunization described in Chapter 3.1. 
At the same time, to examine expansion of memory T cells, we infected the vaccinated 
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mice with 1x10
3
 L. monocytogenes and compared CD8
+
 T cell responses 7 days later 
between control, K
d
/LLO91-99 SCTs, and L. monocytogenes-immune mice. Mice 
immunized with K
d
/LLO91-99 SCTs had 4-6 times more tetramer positive CD8
+
 T cells 
that were CD44
hi
 as well as IFN producing CD8+ T cells that were CD62Llo than L. 
monocytogenes- or control SCTs -immune mice (Fig. 19). Therefore, the results indicate 
that DNA immunization of K
d
/LLO91-99 SCTs generates functional memory CD8
+
 T cells 
that expand rapidly and provide protection against L. monocytogenes infection. 
 
Role of CD4
+
 helper T cells for the SCT-induced CD8
+
 T cells 
We have observed that expression of only CD8
+
 T cell antigens by SCTs is able to 
generate functional memory CD8
+
 T cells. Generally, functional memory CD8
+
 T cells 
are known to require the presence of CD4
+
 helper T cells. Although it is not clear yet how 
CD4
+
 T cells help to generate and maintain CD8
+
 T cell function, it has been reported that 
memory CD8
+
 T cell responses are defective when CD4
+
 T cells are absent during the 
priming phase [102, 103]. In these studies CD8
+
 T cells were primed with infectious 
antigens, which is not the case in our study. It is possible that the CD8
+
 T cell responses 
we saw after SCT immunization could be enhanced by the presence of activated CD4
+
 T 
cells. To determine whether CD4
+
 T cells make SCT-induced CD8
+
 T cell responses 
better, we designed DNA constructs that express CD4
+
 T cell epitopes with SCTs 
simultaneously (Fig. 20A). CD4
+
 T cell epitopes were expressed in the context of an 
invariant chain (Ii) where a CLIP sequence was replaced with a CD4
+
 T cell epitope 
sequence in order for it to be loaded onto MHC II in the appropriate endocytic 
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compartment. Expression of CD4
+
 T cell epitopes and induction of specific CD4
+
 T cells 
using this strategy have been previously reported [41, 129-131]. The CD4
+
 T cell 
epitope/Ii was co-expressed with SCTs using an internal ribosomal entry site (IRES). Two 
different CD4
+
 T cell helper epitopes were used in the study. One is the peptide LLO 189-
201 (one of the dominant CD4
+
 T cell epitopes of L. monocytogenes that binds to MHC II 
I-A
d
) and the other is the pan CD4
+
 helper T cell epitope (PADRE). Mice were 
immunized as above and CD4
+
 and CD8
+
 T cell responses and bacteria control were 
compared among groups immunized with SCTs alone, SCTs plus LLO189-201, and SCTs 
plus PADRE after challenge with L. monocytogenes.  
First, I was able to confirm the induction of epitope-specific CD4
+
 T cells at one 
week post-immunization by measuring IFN and IL-2 production after in vitro peptide re-
stimulation of splenocytes from the immunized mice (Fig. 20B). Both CD4
+
 helper T cell 
epitopes induced a comparable level of CD4
+
 T cell response, as monitored after in vitro 
expansion. All three groups showed similar CD8
+
 T cell responses in terms of the number 
of K
d
/LLO91-99 tetramer positive cells as well as IFN production (Fig. 20B). These results 
indicated that the presence of activated CD4
+
 T cells did not affect the primary CD8
+
 T 
cell response. Next, memory CD8
+
 T cell responses were examined.  
At 6 weeks post-immunization, about the same number of memory phenotype, 
CD44
hi
, CD62L
lo
 and K
d
/LLO91-99 tetramer positive CD8
+
 T cells were present in all three 
groups and they produced a comparable amount of IFN upon in vitro peptide re-
stimulation (Fig. 21A). However, after challenge with 1x10
3
 of L. monocytogenes, mice 
that had been vaccinated with SCTs plus LLO189-201 or SCTs plus PADRE showed larger 
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IFN-producing CD8+ T cell responses than mice vaccinated with SCTs alone (Fig. 21B). 
SCTs plus LLO189-201 and SCTs plus PADRE mounted similar recall responses, indicating 
that CD4
+
 T cell help is not necessarily antigen-specific. Finally, the vaccinated mice 
were challenged with 5x10
4 
L. monocytogenes and 3 days later bacteria in the spleen and 
liver were counted. Mice that had been vaccinated with SCTs plus LLO189-201 or SCTs 
plus PADRE showed no significantly different bacteria counts, indicating that they were 
able to control bacterial infection equally (Fig. 22).  However, mice in both groups had 
about 10-fold less bacteria than mice vaccinated with SCTs alone. Therefore, DNA 
immunization of K
d
/LLO91-99 SCTs generates functional memory CD8
+
 T cells and 
expression of CD4
+
 helper T cell epitopes can further enhance the protective efficacy of 
SCTs. 
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Figure Legends 
 
Figure 18. A SCT DNA vaccine develops memory CD8
+
 T cells 
Mice were vaccinated with K
d
/LLO91-99 SCTs or control K
d
 SCTs as described above and 
rested for 5 months before L. monocytogenes challenge. (A) At 5 months post-
immunization, splenocytes were stained with anti-CD8, -CD44 mAb and SVG9/HLA-
A*0201 tetramers. In the left panels CD3 positive cells are shown and the numbers 
indicate the percentage of CD3
+
 CD8
+
 tetramer
+
 cells. In the right panels CD3
+ 
CD8
+
 
cells are shown and the numbers indicate the percentage of cells in each quadrant. 
Representative figures of the flow cytometry data. (B) Splenocytes from each group were 
stimulated in vitro with LLO 91-99 or irrelevant peptide overnight and IFN secretion 
was measured by ELISPOT. Error bars indicate SE of the experiment. The data presented 
are from one representative experiment of two performed independently with each group 
containing 4~5 mice. (C) Vaccinated mice were infected with 5 x 10
4
 L. monocytogenes 
and 3 days later spleens and livers were harvested and bacteria growth was determined by 
colony count. Error bars indicate SEM of the experiment. Data were expressed as log10 
of colony forming units (CFU). n.s., not significant. *, p<0.05 (unpaired t test). 
 
Figure 19. A SCT DNA vaccine develops functional memory CD8
+
 T cells 
Mice were vaccinated with control K
d
, K
d
/LLO91-99 SCTs, or 10
3
 L. monocytogenes and 5 
months later challenged with 10
3
 L. monocytogenes. At 7 days post-infection, splenocytes 
were stained with anti-CD8, -CD44 mAb, and K
d
/LLO91-99 tetramers (left) or with anti-
CD8, CD62L and -IFN mAb after 4 hour stimulation in vitro with LLO or irrelevant 
91 
 
peptide in the presence of Golgi-blocking agent [87]. CD8 positive cells were shown. 
Numbers indicate the percentage of cells of the gated population among CD8
+
 cells. 
Representative figures of the flow cytometry data. 
 
Figure 20. Co-expression of a CD4
+
 T cell epitope does not affect primary CD8
+
 T 
cell responses 
(A) Diagrams of the plasmid DNA encoding K
d
/LLO91-99 SCT and a CD4 epitope. PCMV, 
promoter; IRES, internal ribosomal entry site; Ii, invariant chain. (B) Mice were 
immunized with DNA encoding K
d
/LLO91-99 SCT only, SCT plus Ii-LLO 198, or SCT 
plus Ii-PADRE three times at 3 day intervals by gene gun. At 5 days after the last 
immunization, splenocytes were harvested. Splenocytes were stained with anti-CD8, -
CD3 mAb, and K
d
/LLO91-99 tetramers [86] or anti-CD8, -CD3, and -IFN mAb after 4 
hour stimulation in vitro with LLO 91-99 or irrelevant peptide in the presence of Golgi-
blocking agent (middle). Numbers indicate the percentage of the cells in the quadrant 
among CD8
+
 cells. Or splenocytes were cultured in vitro in the presence of 1g/mL of 
LLO 198 or PADRE peptide for 5 days and then stained with anti-CD3, -CD4, and -IL-2 
mAb after 4 hour re-stimulation with each peptide in the presence of Golgi-blocking 
agent (lower). Numbers indicate the percentage of the gated cells of CD3
+
 cells. CD3
+
 
cells are shown. Representative figures of the flow cytometry data. 
 
Figure 21. Co-expression of a CD4
+
 T cell epitope increases memory CD8
+
 T cell 
responses 
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Mice were immunized with DNA encoding K
d
/ LLO91-99 SCT only, SCT plus Ii-LLO 198, 
or SCT plus Ii-PADRE as described above. (A) At 6 weeks post-immunization, spleens 
were harvested and stained with anti-CD8, -CD44 mAb and K
d
/LLO91-99 tetramers. 
Percentage of tetramer
+
 CD44
hi
CD8
+
 T cells of four mice in each group was shown (left). 
Or splenocytes were stained with anti-CD8, CD62L and -IFN mAb after 4 hour 
stimulation in vitro with LLO or irrelevant peptide in the presence of Golgi-blocking 
agent [87]. Error bars indicate SD. n.s., not significant (unpaired t test). (B) At 6 weeks 
post-immunization, mice were challenged with 1x10
3
 of L. monocytogenes. 7 days later, 
splenocytes were stained with anti-CD8, -CD3, and -IFN mAb after 4 hour stimulation 
in vitro with LLO 91-99 or irrelevant peptide in the presence of Golgi-blocking agent 
(lower). CD3 positive cells are shown. Numbers indicate the percentage of the cells in the 
quadrant among CD8
+
 cells. Representative figures of the flow cytometry data. 
 
Figure 22. Co-expression of a CD4
+
 T cell epitope enhances the protective efficacy of 
a SCT DNA vaccine 
Mice were immunized with DNA encoding K
d
/ LLO91-99 SCT only, SCT plus Ii-LLO 198, 
SCT plus Ii-PADRE, or 10
3
 L. monocytogenes as described above. At 6 weeks post-
immunization, mice were infected with 5 x 10
4
 L. monocytogenes and 3 days later spleens 
and livers were harvested and bacteria growth was determined by colony count. Error 
bars indicate SEM of the experiment. Data were expressed as log10 of colony forming 
units (CFU). n.s., not significant. *, p<0.05 (unpaired t test). 
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Figure 18. A SCT DNA vaccine develops memory CD8
+
 T cells 
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Figure 19. A SCT DNA vaccine develops functional memory CD8
+
 T cells 
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Figure 20. Co-expression of a CD4
+
 T cell epitope does not affect primary CD8
+
 T 
cell responses 
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Figure 21. Co-expression of a CD4
+
 T cell epitope increases memory CD8
+
 T cell 
responses 
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Figure 22. Co-expression of a CD4
+
 T cell epitope enhances the protective efficacy of 
a SCT DNA vaccine 
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Discussion 
The SCT format has been amenable to different MHC I/peptide complexes, both 
murine and human, and it is one of the intriguing properties of SCTs. Here, we add to the 
list a SCT with the H-2K
d
 haplotype, confirming the potential use of SCTs in clinical 
applications. Like other SCTs previously reported, K
d
/LLO91-99 SCTs were properly 
folded and expressed at the cell surface after transfection and activated T cells in vitro 
and primed peptide-specific CD8
+
 T cells in vivo. This supports the universal application 
of SCTs and therefore the potential as a DNA vaccine platform. 
I demonstrate that K
d
/LLO91-99 SCT DNA vaccination provides protection against 
lethal L. monocytogenes infection. A partial protection by CTLs specific for LLO 91-99 
was previously shown in the study where CTLs from mice vaccinated with plasmid DNA 
encoding the LLO 91-99 epitope were in vitro expanded and adoptively transferred into 
naïve mice prior to L. monocytogenes challenge [132]. As discussed in Chapter 1, SCT-
based DNA vaccines have been proven more effective at generating CD8
+
 T cell 
immunity than epitope-only DNA vaccines due to incorporation of a preprocessed and 
preloaded peptide [21, 30, 31]. We expect that DNA vaccination with K
d
/LLO91-99 SCTs 
would be more efficacious at conferring protection than a plasmid encoding LLO 91-99 
and it will be interesting to compare these different approaches directly. 
Generation of functional memory responses is essential to develop successful 
vaccines against pathogens and considerable effort has been made in developing 
strategies to induce high frequencies of memory T cells [133]. I showed that DNA 
vaccination with K
d
/LLO91-99 SCTs generates functional memory CD8
+
 T cells. In fact, 
99 
 
K
d
/LLO91-99 SCT DNA vaccine developed more memory CD8
+
 T cells and a better recall 
response than immunization with a low dose of live L. monocytogenes. But, the SCT 
DNA vaccine failed to provide mice the same level of protection as live bacteria-
immunization. This might be because LLO 91-99 is just one of the many 
immunodominant epitopes of L. monocytogenes in BALB/c mice. Although LLO 91-99 
seems most immunodominant among many others, the immunodominance is not absolute. 
For example, p60 217-225 derived from p60, a murein hydrolase secreted by bacteria into 
the cytosol, induces a slightly smaller but substantial CD8
+
 T cell response than LLO 91-
99 [113, 114]. Also, other immune components besides CD8
+
 T cells play a role in 
controlling L. monocytogenes infection. For example, neutrophils and macrophages are 
thought to be the principal mediators of the killing of L. monocytogenes at early infection 
[134-136]. The SCT DNA vaccine is very potent to prime CD8
+
 T cells but it alone may 
not be sufficient to activate all the players involved in pathogen infection. For this reason, 
SCTs should be considered in a composite vaccine targeting multiple aspects of the 
immune system. 
Our study shows that SCT DNA immunization induces a primary CD8
+
 T cell 
response independently of CD4
+
 T cells and it alone can generate functional memory 
CD8
+
 T cells that provide protection against infection. The presence of CD4
+
 T cell help 
improved the recall response and protective efficacy marginally. In the literature, there 
has been agreement that primary CD8
+
 T cell responses do not depend on CD4
+
 T cell 
help [102, 103, 137], which is consistent with our results. However, role of CD4
+
 T cell 
help for the generation of stable, protective CD8
+
 T cell memory is still controversial. In 
100 
 
the studies supporting a requirement for CD4
+
 T cell help for the generation of CD8
+
 T 
cell memory [101-103, 119], CD8
+
 T cells developed in the absence of CD4
+
 T cells 
using MHC class II- or CD4-knockout mice, whereas CD4
+
 T cells were present during 
SCT-induced CD8
+
 T cell generation in our study. Indeed, Bevan et al. demonstrated that 
effector CD8
+
 T cells became functionally impaired after transfer into MHC II-deficient 
recipients, but not into wild-type recipients [119]. My results that co-expression of CD4
+
 
helper T cell epitopes increased secondary CD8
+
 T cell responses and protective efficacy 
support a crucial role of CD4
+
 T cells for the maintenance of memory CD8
+
 T cells [119]. 
Additionally, the similar extent of augmentation of CD8
+
 T cell responses by LLO 189-
201 and PADRE suggest that CD4
+
 T cell function is not antigen specific. Our results are 
consistent with the study by T. C. Wu et al. where co-administration of Ii-PADRE DNA 
with K
b
 SCT DNA encoding a tumor epitope further enhanced generation of antigen-
specific CD8
+
 T cells and anti-tumor effects against tumor challenge. However, it was not 
identified in this study whether the activated CD4
+
 T cells affected primary or memory 
CD8
+
 T cell responses [41]. 
The mechanism through which CD4
+
 T cells provide help for memory CD8
+
 T 
cells has not been elucidated. In the cytotoxic T cell response to noninfectious agents 
such as immunization with protein antigens, activation of CD4
+
 T cells is important in 
maturation of the antigen presenting cells so that it can promote a CD8
+
 T cell response 
whether CD4
+
 T cells function solely via activation of the antigen presenting cells 
through CD40-CD40L interaction or also via direct CD4-CD8 T cell interaction [138-
140]. Thus the amount of danger signals produced by the immunization seems to be 
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important. Accordingly, in the CTL response to virulent pathogens, the generation of 
memory CD8
+
 T cell precursors is CD4
+
 T cell independent [141, 142]. One of the 
mechanisms for the immune responses by DNA vaccines is the innate responses directed 
against the plasmid itself. Because the plasmid is of bacterial origin, its sequences contain 
CpG oligodeoxynucleotide motifs that bind the pattern recognition receptor Toll-like 
receptor 9 (TLR9), which is constitutively expressed on dendritic cells, with a resultant 
augmentation of the immune response against the antigen encoded by the plasmid [143, 
144]. Although the role of TLR9 in DNA vaccines is still inconsistent between studies 
[145, 146], the role of the CpG motifs in activating DCs may be important for generating 
T cell responses with DNA vaccines.  
We hypothesize that SCT DNA immunization may not largely depend on CD4
+
 T 
cell help because of the adjuvant effect of CpG motifs from bacterial plasmid and/or high 
density epitope/MHC I expression at the cell surface. It has been reported that gene-gun 
administration of DNA stimulates a type 2 immune response due to the low amount of 
DNA injected, consequently fewer CpG motifs, whereas a type 1 immune response is 
critical to clear intracellular bacteria like L. monocytogenes [147-149]. However, our data 
show that SCT DNA vaccination using the gene-gun method can provide protection 
against L. monocytogenes. We speculate that it is likely that the high density expression 
of antigens at the cell surface using a SCT format overcomes the limited adjuvant.  
In conclusion, our study demonstrates that SCTs can serve as a potent platform for 
DNA vaccines to develop CD8
+
 T cell immunity in various disease models including 
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virus as well as bacterial infection. Furthermore, our combined WNV and Listeria data 
demonstrate that SCT DNA vaccines are largely CD4 helper cell independent. 
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Chapter 4. 
Improvement of SCT-based DNA vaccines 
 
Introduction 
Vaccination with plasmid DNA encoding a SCT has been shown to be superior for 
eliciting CD8
+
 T cell responses compared with DNA encoding an immunodominant 
peptide or the unprocessed protein from which the immunodominat peptide is derived [21, 
30, 31]. However, the capacity of a SCT may be further improved by increasing stability 
of the SCT at the cell surface or targeting its expression to cell types critical for T cell 
priming. Improving peptide anchoring within the SCT is especially relevant when the 
antigenic peptide has very low affinity. Although a weak binding peptide, such as the p5Y 
variant of OVAp, was used to make an SCT detected by OT-1 T cells, this SCT was more 
susceptible to peptide displacement than an SCT incorporating the native OVAp [23]. 
These comparisons demonstrated that SCTs incorporating tight binding peptides were 
more stable suggesting they may also make better vaccines. 
Our lab, in collaboration with the Fremont lab, has taken a structure based 
approach to re-engineer the SCT format to better accommodate a peptide in the peptide 
binding groove of MHC I. The crystal structure of the H-2K
b
/OVAp SCT showed that the 
anchoring of the C-terminus of the OVA peptide within the F pocket of K
b
 was disrupted 
[25]. More specifically, the peptide-2m linker extending from the C terminal peptide 
residue disrupts the canonical hydrogen binding network conserved among all published 
structures of MHC I/protein complexes. Most significantly, a protrusion of the peptide-
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β2m linker was imposed by the highly conserved MHCI residue Tyr-84 that is integrally 
involved in C terminal peptide anchoring. These observations of the SCT structure 
explain why the K
b
/OVAp SCT is more susceptible to peptide exchange than native 
K
b
/OVAp complexes [22]. To improve linker accommodation and peptide binding with 
the SCT, a disulfide bond judiciously incorporated between the linker and a residue at the 
C-terminal end of the peptide binding groove of heavy chain (disulfide trap- or dt- SCT) 
enhanced the stability of the original K
b
/OVAp SCT while preserving TCR interactions 
[23-25]. Here, I examined whether a disulfide trap can improve SCTs that are poorly 
recognized by T cells. Collaborative efforts of the Hansen, Diamond, and Fremont labs 
and others have published immunodominant WNV epitopes presented by H-2K
b
 
molecules of C57BL/6 mice to CD8
+
 T cells [72, 73]. WNVp3, IALTFLAV, is one of the 
immunodominant CD8
+
 T cell epitopes that binds to H-2K
b
 and is processed from the 
viral E protein. A H-2K
b
/WNVp3 SCT was constructed and a high level of surface 
expression of this SCT was achieved after transfection in vitro. Surprisingly, the SCT was 
not recognized by peptide-specific CD8
+
 T cells. This failure was surprising because our 
lab and others have reported the universal application of the SCT format to all MHC 
I/peptide complexes studied thus far. These reported SCTs included 3 made with K
b
 and 
different antigenic peptides [18]. It is noteworthy that WNVp3 is not a particularly avid 
binder compared to SIINFEKL of ovalbumin that also binds to H-2K
b
. Thus, a 
K
b
/WNVp3 dtSCT was considered a good model to determine whether a difficult SCT 
can be improved by incorporating a disulfide trap. 
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Targeting of delivery, not just to the antigen processing pathway but to particular 
cells or subsets of cells is an important factor for increasing the potency of vaccines. It 
can be achieved better with DNA plasmids as vaccine vectors which are relatively easy to 
manipulate. However, the mechanism by which antigens are presented after DNA 
vaccination is controversial. While some studies suggested direct presentation where 
transfected APCs, i.e. dendritic cells (DCs), trafficking to the draining lymph nodes 
express and present antigens to T cells [49], many studies have speculated that cross-
presentation is involved in priming T cells following DNA vaccination [50, 51, 150-152]. 
If T cell priming occurs via cross-presentation of antigens after DNA vaccination, SCTs 
would still induce specific T cells but it is not clear why they should be better than a 
peptide or a protein as reported [21, 30, 31].  If the antigen with the SCT is indeed cross-
presented, it is possible that the SCT may only stabilize the peptide within the original 
cell taking up the DNA or that a mechanism of cross-presentation involves the transfer of 
the entire SCT complex.  To probe the mechanism by which antigen is presented by the 
SCT, we used a dtSCT and an original SCT using peptides that cannot be cross-presented.    
In this chapter, I demonstrated that K
b
/WNVp3 SCT became more resistant to 
replacement by exogenous competitor peptides and its recognition by T cells improved 
with a disulfide trap. Also my data showed that the SCT with a weak binding peptide 
OVAp5Y, which did not prime T cells when introduced as cDNA, induced CD8
+
 T cell 
responses after DNA vaccination, indicating SCTs are presented as intact molecules.  
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Materials and Methods 
1. SCT construct  
SCTs consist of the leader sequence of 2m followed by the epitope sequence, 
then a linker of 15 residues (G4S)3, and the mature mouse 2m sequence. The 2m was 
followed by the second linker of 20 residues (G4S)4 and the heavy chain of H-2K
b
. To 
generate H-2K
b
/WNVp3 SCT, H-2K
b
 SCT with SIINFEKL peptide was used as a 
template. Nucleotide oligos encoding West Nile virus peptide, p3 (IALTFLAV), flanked 
by Age1 and Nhe1 restriction enzyme sites were designed; 5’- 
CCGGTTTGTATGCTATCGCCCTCACCTTCCTAGCCGTCGGAGGAGGTG -3’ and 
5’- CTAGCACCTCCTCCGACGGCTAGGAAGGTGAGGGCGATAGCATACAAA -3’. 
Oligos were annealed to form double strands and inserted into the 
pIRESneo.OVA.mB2mb.etK
b
 cut with Age1 and Nhe1. Then the fragment containing p3 
sequence was excised using Not1 and EcoR1, and inserted into pMIN.OVA.mB2mb.K
b
 
cut with the same restriction enzymes. To introduce a disulfide bond between the linker 
and the heavy chain, the second amino acid, glycine, of the first linker was mutated to 
cysteine and tyrosine at residue 84 of K
b
 heavy chain was also mutated to cysteine by 
site-directed mutagenesis. The correct sequence was confirmed by DNA sequencing 
using BigDye 3.1 (Washington University, St. Louis, MO).  
Generation of HLA-A2/WNV SVG9 SCTs was described in Chapter 2.2. The 
original and disulfide trap SCT of H-2K
b
/OVAp5Y have been previously described [21, 
23]. 
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2. Generation of stable cell line expressing SCTs 
Transient transfection was performed on 293T human embryonic kidney cells 
using Lipofectamine 2000 (Invitrogen) to generate retrovirus-containing supernatants for 
infection and mouse fibroblast LM1.8 cells were used for retroviral transduction of SCTs. 
SCT-expressing cells were sorted through flow cytometry post transduction. All cells 
were maintained in DMEM (Invitrogen) supplemented with 10% FBS (HyClone 
Laboratories, Logan, UT), 2mM L-glutamine, 0.1mM non-essential amino acids, 
1.25mM HEPES, 1mM sodium pyruvate, and 100U/mL penicillin/streptomycin (all from 
the Tissue Culture Support Center, Washington University School of Medicine, St. Louis, 
MO). 
 
3. Antibodies and flow cytometry 
Cell culture supernatant containing the following monoclonal antibodies were 
used to stain SCTs at the surface; anti-H-2K
b
 (B8-24-3), anti-K
b
/OVAp (SIINFEKL) (25-
D1.16), anti-H-2D
k
 or K
k
 (15-5-5). About 10
6
 cells per sample were incubated on ice in 
microtiter plates with primary mAb for 30min. After washing with PBS containing 1% 
BSA, PE-conjugated goat anti-mouse IgG (BD Pharmingen) was added as secondary Ab 
for 20min. Analyses were performed using a FACSCalibur (BD Biosciences). Dead cells 
and debris were excluded from analysis on the basis of forward-angle and side-scatter 
light gating. Data were analyzed using FlowJo software (Tree Star). 
 
4. Generation of a CD8
+
 T cell line 
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For generation of bulk CTL clones, C57BL/6 mice were infected subcutaneously 
by footpad injection with 10
2
 PFU of WNV (strain 3000.0259). 4 weeks after infection, 
splenocytes were harvested, washed with medium (RPMI 1640 containing 10% FBS), 
and resuspended at 7.5x10
6
 cells/mL. In parallel, splenocytes from uninfected congenic 
TAP
–/–
 C57BL/6 mice were harvested, depleted of erythrocytes with ACK buffer (0.15 M 
NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA), washed with RPMI medium, irradiated 
(2000 rad), and counted. TAP
–/–
 splenocytes were resuspended at 3.5x10
6
 cells/mL and 2 
M peptide, WNVp3, was added. CTL were generated by incubating immune 
splenocytes with peptide-pulsed TAP
–/–
 splenocytes at a final peptide concentration of 1 
M in a 24-well tissue culture plate. Seven days later, CTL were restimulated with 
3.5x10
6
 irradiated TAP
–/–
 splenocytes pulsed with 1 M WNVp3. At day 14 and 
thereafter, bulk CTL against WNVp3 were stimulated at weekly intervals with irradiated 
wild-type splenocytes, 1 M peptide, and 10 U/mL rIL-2. 
 
5. CTL assay 
At day 5 after stimulation, CTLs were assayed for their ability to lyse target cells. 
To perform a 
51
Cr release assay, target cells were labeled with 0.2 mCi of 
51
Cr 
(PerkinElmer Life Sciences, Waltham, MI) for 1 hour and incubated with CTLs with or 
without peptides for 4 ½ hours at 37C. To determine maximum lysis, Triton-X 100 was 
added to control wells. To determine spontaneous lysis, target cells were incubated 
without CTLs. Supernatants were collected and read by an Isomedic -counter (ICN 
Biomedicals). The percentage of 
51
Cr release was calculated by [(experimental 
51
Cr 
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release-spontaneous 
51
Cr release)/(maximum 
51
Cr release-spontaneous 
51
Cr release)] 
x100. 
 
6. Peptide competition assay 
For the competition assay, serially diluted SIINFEKL peptide from 250 to 0.24M 
was incubated with 2x10
5
 LM1.8 cells expressing SCTs in a 96 well round-bottom plate 
for 4 hours at 37C. Cells were then washed three times with PBS containing 1%BSA 
and stained with B8-24-3 for total K
b
 or 25-D1.16 for K
b
/SIINFEKL. 
 
7. Mice and DNA immunization 
For the immunization of HLA-A2/WNV SVG9 SCTs, HHDII transgenic (B6; Cg-
B2M
tm1Unc
 H2-D1
tm1Bpe
Tg (HLA-A/H2-D/B2M)1Bpe) mice were used (described in 
Chapter 2.1). For the immunization of H-2K
b
/OVAp or H-2K
b
/WNVp3 SCTs, C57BL/6 
mice were purchased from the Jackson Laboratory (Bar Harbor, Maine). All mice were 
bred and housed at the Washington University Animal Facility and all animal procedures 
were approved by the Animal Studies Committee at Washington University. 
DNA-coated gold particle-mediated DNA vaccination was performed using a 
helium-driven gene gun (Bio-Rad). DNA-coated gold particles (diameter, 1m) and 
cartridges were prepared according to the manufacturer’s instructions so that each 
cartridge contained 1g of DNA. The DNA-coated gold particles were delivered to the 
shaved abdomen of mice with a discharge pressure of 200 psi. Mice were immunized 
with 4g of DNA three times at 3 day intervals.  
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8. IFN ELISpot assay 
Spleens were harvested from mice 5 days after the last DNA immunization. After 
RBC lysis, single cell suspensions were incubated with 1g/mL SVG9 or control 
peptides in a PVDF filter plate (Millipore) pre-coated with 15g/mL of anti-IFN capture 
antibody (AN18, Mabtech Inc, Cincinnati, OH). After overnight stimulation, cells were 
removed and the plate was incubated with biotinylated anti-IFN detection antibody (R4-
6A2) and subsequently with streptavidin-ALP. Then spots were developed by adding 
substrate solution (BCIP/NBT) and counted with an automated ELISpot reader. 
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Chapter 4.1 
Trapping peptide by disulfide bond can improve difficult SCTs 
 
Results 
Peptide binding groove of K
b
/WNVp3 SCTs is readily accessible 
K
b
/WNVp3 SCTs were expressed in LM1.8 cells, which express H-2
k
 
endogenously, by viral transduction. SCTs were properly folded and expressed at the cell 
surface, which was determined by staining with mAb specific for K
b
 with a folded 
conformation (Fig. 23A). To examine whether SCTs are recognized by peptide-specific 
CD8
+
 T cells, a stable cell line was generated after sorting of high K
b
 expressers by FACS. 
After sorting, SCT (K
b
) expression at the cell surface was as high as the expression level 
of endogenous MHC I, D
k
 (Fig. 23A). However, K
b
/WNVp3 SCTs showed no killing by 
WNVp3-specific CD8
+
 T cells (Fig. 23B). It was surprising that SCTs were not 
recognized by T cells despite their high surface expression and properly folded 
conformation. Thus we speculated that the peptide in the peptide binding groove of SCT 
may be rapidly displaced by other peptides and/or extrusion of the peptide-2m linker 
somehow obstructs optimal interaction with the TCR. To examine how secure the epitope 
binding to K
b
 in SCTs is, I performed a peptide competition assay using OVAp, 
SIINFEKL. If the binding of WNVp3 to the binding groove of heavy chain is stable, 
peptides added exogenously would be able to displace WNVp3 and bind to MHC of SCT 
only at high concentration. Although it was not as easily accessible as K
b
 alone, WNVp3 
in K
b
/WNVp3 SCT was certainly being displaced by exogenous SIINFEKL at as low a 
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concentration as 2M (Fig. 23C). Thus, weak binding of the peptide in the SCT is likely 
one reason for the failure of T cell recognition. 
 
Securing WNVp3 into the peptide binding groove of the SCT with a disulfide-trap 
potentiates CTL recognition 
It is likely that insecurely bound peptide and protrusion of the attached linker 
hinders the proper engagement of SCTs with TCR. We knew from western blot analysis 
that the majority of K
b
/WNVp3 SCTs are still expressed as one polyprotein with a 
covalently linked 2m (data not shown). Thus, to lock the peptide in the binding groove 
of the MHC heavy chain, a disulfide trap was introduced. A glycine residue at the first 
linker and a tyrosine residue, Y
84
, in the MHC I heavy chain, which is located at the C-
terminal end of the peptide-binding cleft, were mutated to cysteine so that a disulfide 
bond was formed between the two residues (Fig. 24). This disulfide bond would close the 
C-terminal end of the binding groove and secure the peptide [23, 25]. The addition of a 
disulfide bond did not increase the expression of K
b
/WNVp3 dtSCT at the surface in 
comparison with K
b
/WNVp3 SCTs as analyzed by flow cytometry (Fig. 25A). However, 
K
b
/WNVp3 dtSCTs were resistant to displacement by exogenous OVAp (Fig. 25B) and 
now peptide-specific CD8
+ 
T cells were able to lyse cells expressing K
b
/WNVp3 dtSCTs, 
indicating that the SCT was recognized (Fig. 25C). Thus, our data suggest that 
engineering with a disulfide trap can increase peptide occupancy and recognition of SCTs 
by T cells. Interestingly, these data represent the first example we are aware of where a 
disulfide trap is required for CD8
+
 T cell detection of an SCT. Mechanistically, this is a 
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very intriguing observation, because as shown in the next section, an SCT made with a 
poor binding variant of the OVAp is detected by CD8
+
 T cells with and without a 
disulfide trap. Implications of these combined findings are included the Discussion 
section of this chapter. 
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Figure Legends 
 
Figure 23. K
b
/WNVp3 SCTs are expressed but do not activate peptide-specific CD8
+
 
T cells  
LM1.8 cells expressing K
b
/WNVp3 SCTs were generated by virus transduction and 
selection through FACS sorting. (A) Cell surface expression of K
b
/WNVp3 SCTs. Cells 
were stained with anti-K
b
 mAb (B8-24-3, solid line) or anti-K
k
 mAb (15-5-5, dotted line). 
A shaded histogram shows staining of non-transduced LM1.8 cells with anti-K
b
 mAb. (B) 
LM1.8 cells expressing K
b
 or K
b
/WNVp3 SCTs were used as targets in a 
51
Cr-release 
assay with WNVp3-specific CTLs. For a control, K
b
-expressing LM1.8 cells pulsed with 
WNVp3 were also used as targets. (C) LM1.8 cells expressing K
b
 (circle) or K
b
/WNVp3 
SCTs (square) were incubated with serially diluted SIINFEKL peptide from 250 to 
0.24M for 4 hours. Total amount of Kb at the cell surface was measured by staining 
with anti-K
b
 mAb (B8-24-3) and the amount of K
b
/SIINFEKL complexes were measured 
by staining with anti-OVAp/K
b
 mAb (25-D1.16). Data were presented as the percentage 
of K
b
/SIINFEKL molecules of total K
b
 molecules at the cell surface. 
 
Figure 24. Diagram of the H-2K
b
/OVAp dtSCT 
Figures were taken from the article, ‘Structural engineering of p MHC reagents for T cell 
vaccines and diagnostics’ by Mistaksov V. and Truscott S. [25]. (A) Diagram of Kb/OVAp 
SCTs with a disulfide trap (dtSCT). In the ribbon diagram, OVAp and the peptide-2m 
linker were rendered as ball-and-stick models and colored as follows; OVAp and linker 
carbon atoms, yellow and orange, respectively; nitrogen atoms, blue; oxygen atoms, red. 
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The possible conformation for the 2m-heavy chain linker was represented as small 
orange balls. (B) CPK model of the surface of the peptide binding grooves of K
b
/OVAp 
SCT (left) and K
b
/OVAp dtSCT (right). The solvent-accessible surfaces of the peptide-
binding grooves were displayed as blue dotted surface. K
b
 pocket locations were 
indicated underneath each surface. The peptide-2m linker residues were labeled L1 
through L6 or L9. 
 
Figure 25. A disulfide trap improves stability and T cell recognition of K
b
/WNVp3 
SCTs 
(A) Cell surface expression of K
b
/WNVp3 dtSCTs. LM1.8 cells were transfected with 
K
b
/WNVp3 SCTs with (dotted line) or without a disulfide trap (solid line) and stained 
with anti-K
b
 mAb (B8-24-3). A shaded histogram shows staining of untransfected LM1.8 
cells with anti-K
b
 mAb. (B) LM1.8 cells expressing K
b
 (circle) or K
b
/WNVp3 dtSCTs 
(square) were incubated with serially diluted SIINFEKL peptide from 250 to 0.24M for 
4 hours. Total amount of Kb at the cell surface was measured by staining with anti-K
b
 
mAb (B8-24-3) and the amount of K
b
/SIINFEKL complexes were measured by staining 
with anti-OVAp/K
b
 mAb (25-D1.16). Data were presented as the percentage of 
K
b
/SIINFEKL molecules of total K
b
 molecules at the cell surface. (C) LM1.8 cells 
expressing K
b
, K
b
/WNVp3 SCTs, or dtSCTs were used as targets in a 
51
Cr-release assay 
with WNVp3-specific CTLs. For a control, K
b
-expressing LM1.8 cells pulsed with 
WNVp3 were also used as targets. 
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Figure 23. K
b
/WNVp3 SCTs are expressed but do not activate peptide-specific CD8
+
 
T cells  
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Figure 24. Diagram of the H-2K
b
/OVAp dtSCT 
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Figure 25. A disulfide trap improves stability and T cell recognition of K
b
/WNVp3 
SCTs 
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Chapter 4.2 
SCTs are presented as intact structures 
 
Results 
Chimeric HLA-A2/D
b
 α3 SCTs are better than intact HLA-A2 SCTs for induction of CD8+ 
T cells by DNA immunization in HHDII mice 
In Chapter 2.2, I showed that the SCT of a West Nile virus epitope SVG9 and 
HLA-A2 induces epitope-specific CD8
+
 T cell responses after DNA immunization in 
HLA-A2 transgenic (HHDII) mice. Because the HHDII mouse expresses no human CD8 
but does express mouse CD8 co-receptors and chimeric HLA-A2 molecules, in which the 
α3 domain is replaced with that of H-2Db, SCTs for DNA immunization were also 
constructed to have the same chimeric A2/D
b
 α3. It has been reported that the interaction 
between a CD8 co-receptor of a TCR complex and α3 domain of MHC I heavy chain is 
required to prime naïve CD8
+
 T cells and there is some species specificity in the 
interaction of CD8 with the 3 domain of the class I molecule [153-155]. Especially, 
Engelhard et al. demonstrated that CTL lines from HLA-A2 transgenic mice 
preferentially recognize class I molecules with a murine 3 domain at low concentrations 
of peptide in vitro [154]. Thus, it is expected that a chimeric A2/D
b
 α3 SCT DNA vaccine 
would prime naïve CD8
+
 T cells better than an intact HLA-A2 SCT in the HHDII HLA-
A2 transgenic mouse, but only if the SCTs remain intact for presentation. However, if the 
SCTs require processing and re-loading onto the endogenous MHC class I of an APC not 
taking up the DNA, i.e. cross-presentation, both chimeric A2/D
b
 α3 SCTs and intact A2 
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SCTs would result in priming CD8
+
 T cells equally in the transgenic mice. To determine 
whether SCTs are presented as intact molecules or cross-presented to T cells after DNA 
vaccination, I immunized HHDII mice with either chimeric A2/D
b
 α3/ or intact A2/SVG9 
SCT DNA using the gene gun, as described in the previous chapters, and compared IFN 
responses of CD8
+
 T cells upon in vitro peptide re-stimulation at 5 days post 
immunization. The results show that the chimeric A2/D
b
 α3/SVG9 SCTs induced stronger 
CD8
+
 T cell responses than intact A2/SVG9 SCTs, indicating SCTs were presented to T 
cells as intact molecules (Fig. 26). 
 
H-2K
b
/p5Y SCTs, but not p5Y, induce OVA-specific CD8
+
 T cells after DNA immunization 
OVAp5Y, SIINYEKL, is an altered peptide ligand of SIINFEKL, that binds 
poorly to H-2K
b
 because of a mutation at position 5, an anchor residue for MHC I 
binding. Half-time for dissociation of SIINYEKL from K
b
 at the cell surface is 120 
minutes while half-time of SIINFEKL is 360 minutes, indicating SIINYEKL has very 
low binding affinity to K
b
 [156]. But OVAp5Y is still recognized by SIINFEKL-specific 
OT-1 T cells in the context of K
b
 [157, 158]. Studies in our lab showed that K
b
/OVAp5Y 
dtSCTs are expressed well at the cell surface after transfection and efficiently exclude 
exogenous competitor peptides from binding [23]. Thus, we speculated that a 
K
b
/OVAp5Y dtSCT would be able to prime peptide-specific CD8
+
 T cells if it were 
presented intact following DNA immunization. We also speculated that the p5Y peptide 
from the K
b
/OVAp5Y dtSCT DNA would be incapable of cross-presentation by a native 
K
b
 molecule due to its poor binding affinity. To test whether this was indeed the case, as a 
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control I immunized mice with DNA encoding the OVAp5Y peptide (kindly provided by 
Dr. Lijin Li). As shown in Fig 27, C57BL/6 mice were immunized with DNA encoding 
OVAp5Y, K
b
/OVA SCTs, or K
b
/OVAp5Y SCTs with or without a disulfide trap using 
gene gun. IFN production of OVA-specific T cells in the spleen upon in vitro peptide 
restimulation was measured at day 5. Indeed, OVAp5Y cDNA did not induce any 
detectable T cell responses, demonstrating the p5Y cannot be cross-presented. However, 
all three of the SCT DNA constructs induced equally strong OVA-specific CD8
+
 T cell 
responses (Fig. 27). Therefore, the data demonstrates that SCTs are presented as intact 
structures to T cells following DNA immunization. 
 
H-2K
b
/WNVp3 dtSCTs induce a more robust CD8
+
 T cell response than the H-
2K
b
/WNVp3 SCTs without disulfide trap after DNA immunization. 
With the same logic as above, I compared K
b
/WNVp3 SCTs and K
b
/WNVp3 
dtSCTs for their ability to induce peptide-specific CD8
+
 T cells after DNA immunization. 
C57BL/6 mice were immunized with K
b
/WNVp3 SCTs or K
b
/WNVp3 dtSCT DNA using 
the gene gun and T cell responses were assessed by measuring IFN production upon in 
vitro peptide restimulation. K
b
/WNVp3 SCTs without a disulfide trap induced a few 
IFN-producing cells (Fig. 28), which was consistent with the observation that 
K
b
/WNVp3 SCTs did not activate peptide-specific CD8
+
 T cells in vitro as described in 
Chapter 4.1. On the contrary, K
b
/WNVp3 dtSCTs DNA immunization induced many 
more T cells producing IFN than Kb/WNVp3 SCTs. Thus all three of the above 
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experimental results in this section present cumulative evidence that SCTs are presented 
as intact molecules following DNA immunization. 
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Figure Legends 
 
Figure 26. Chimeric HLA-A2/D
b
 α3 SCTs induce stronger CD8+ T cell responses 
than intact HLA-A2 SCTs in HHDII mice 
HHDII mice were immunized with chimeric A2/Db α3/ or intact A2/SVG9 SCT DNA 
using gene gun as described above. At day 5 after the last immunization, splenocytes 
from each group were stimulated in vitro with SVG9 or irrelevant peptide overnight and 
IFN secretion was measured by ELISPOT. Error bars indicate SE of the experiment. The 
data presented are from one representative experiment of two performed independently 
with each group containing 4~5 mice. *, p<0.05 (unpaired t test). 
 
Figure 27. H-2K
b
/OVAp5Y SCT DNA but not OVAp5Y cDNA immunization primes 
CD8
+
 T cells 
C57BL/6 mice were immunized with OVAp5Y, control K
b
 SCTs, K
b
/OVA SCTs, 
K
b
/OVAp5Y SCTs or K
b
/OVAp5Y dtSCTs using gene gun as described above. At day 5 
after the last immunization, splenocytes from each group were stimulated in vitro with 
OVAp or irrelevant peptide overnight and IFN secretion was measured by ELISPOT. 
Error bars indicate SE of the experiment. The data presented are from one representative 
experiment of two performed independently with each group containing 4 mice. n.s., not 
significant., *, p<0.05 (unpaired t test). 
 
Figure 28. H-2K
b
/WNVp3 dtSCTs induce a more robust CD8
+
 T cell response than 
the H-2K
b
/WNVp3 SCTs. 
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C57BL/6 mice were immunized with control K
b
 SCTs, K
b
/WNVp3 SCTs, or K
b
/WNVp3 
dtSCTs using gene gun as described above. At day 5 after the last immunization, 
splenocytes from each group were stimulated in vitro with WNVp3 or irrelevant peptide 
overnight and IFN secretion was measured by ELISPOT. Error bars indicate SE of the 
experiment. The data presented are from one representative experiment of two performed 
independently with each group containing 4~5 mice. *, p<0.05 (unpaired t test). 
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Figure 26. Chimeric HLA-A2/D
b
 α3 SCTs induce stronger CD8+ T cell responses 
than intact HLA-A2 SCTs in HHDII mice 
126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. H-2K
b
/OVAp5Y SCTs DNA but not OVAp5Y cDNA immunization primes 
CD8
+
 T cells 
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Figure 28. H-2K
b
/WNVp3 dtSCTs induce a more robust CD8
+
 T cell response than 
the H-2K
b
/WNVp3 SCTs. 
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Discussion 
From the previous studies in our lab, we knew that the linker attached antigenic 
peptide in the SCT is constantly rebinding to the peptide binding groove of the MHC 
heavy chain [22, 23, 25]. Structural analyses in collaboration with the Fremont lab 
showed that the impaired peptide binding is due to the first linker of the SCT that extends 
beyond the peptide binding groove. Normally the F pocket in the MHC I heavy chain 
anchors the C terminus of the peptide through conserved interactions, but the first 
peptide-2m linker disrupts many of the conserved interactions. Despite this fact, the H-
2K
b
/OVAp SCT is more stable at the cell surface than native MHC I/peptide complexes 
and exhibits a high level of steady state peptide occupancy. This is because OVAp is a 
particularly high affinity binder and the covalently attached peptide is efficiently 
rebinding after dissociation occurs [22, 23]. Also the continuous rebinding of peptide 
does not seem to affect T cell recognition of K
b
/OVAp SCT. However, our current study 
with a WNV epitope, WNVp3, showed that exogenous peptides can gain access to the 
peptide binding groove of K
b
/WNVp3 SCTs even at a low concentration, implying 
peptide accommodation is severely impaired. Moreover, T cell recognition of SCTs was 
also impaired. It is not likely that the peptide is cleaved from the heavy chain because 
K
b
/WNVp3 SCTs were expressed at high levels at the cell surface and were more 
resistant to displacement by exogenous OVAp than K
b
/ 2m with endogenous peptides. 
This result indicates the peptide binding groove of the K
b
/WNVp3 SCT was occupied, 
but not necessarily with the linker attached peptide. Thus, the failure of the K
b
/WNVp3 
SCT to be detected by CTL could result from i) relatively low affinity of WNVp3 to K
b
,
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ii) hindrance of TCR engagement by peptide-2m linker extrusion, and/or iii) peptide 
registry shift due to the extended C terminus of the peptide. Regarding the first possibility, 
low affinity alone is not likely the explanation, because the OVAp5Y peptide is a poor 
binder yet the SCT incorporating p5Y peptide is detected by T cells. Regarding the 
second possibility, our lab previously showed from analysis of the crystal structure of 
K
b
/OVAp SCT that the extruded peptide-2m linker traverses over the C terminal TCR 
proximal surface of the MHC  helix where a conserved TCR recognition region is [25]. 
Regarding the third possibility, peptide registry shift within the peptide binding groove of 
MHC has been proposed particularly for MHC class II which allows a wide range of 
peptide lengths, which vary between 13 and 17 amino acids although shorter or longer 
lengths are not uncommon, for binding because of the open-ended peptide binding 
groove [159-163]. Peptides are hypothesized to shift within the MHC class II peptide-
binding groove, changing which 9mer register sits directly within the groove. For 
example, Goverman et al. demonstrated that processing of myelin basic protein (MBP) 
produces MBPAc1-18 peptide which utilizes two binding registers to bind I-A
u  
[162]. 
Also Kappler et al. demonstrated that I-A
b
 binds an immunogenic peptide variant stably 
by creating unique interactions, indicating MHC can bind peptide stably in more than one 
way [161]. Because in SCTs the peptide available for binding is extended by its 
covalently attached linker, it is possible that peptides bind the groove with different 
registers so that it cannot be recognized same by peptide-specific T cells.  
Failure of the K
b
/WNVp3 SCT to be recognized by T cells was overcome by 
introducing a disulfide trap in the area of the F pocket of the peptide binding groove. The 
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disulfide trap is engineered to bind the first linker to Y
84
 at the C terminal end of the 
peptide-binding groove of heavy chain so that it locks in the linker-attached peptide and 
keeps the extrusion of the peptide and linker away from TCR interaction surface. 
Structural studies with H-2K
b
/OVAp SCTs showed that the mutation of a heavy chain 
residue, Y
84
, to make a disulfide bond, opens the C terminal end of the peptide-binding 
groove and allows the linker to freely extrude from the peptide-binding platform [22, 23, 
25]. A SCT with a disulfide trap (dtSCT) was more stable and refractory to exogenous 
peptide binding than a SCT without a disulfide trap. Here, I found that the disulfide trap 
rendered K
b
/WNVp3 SCT more resistant to exogenous peptide binding and potentiated 
recognition by T cells. Our finding is of importance in that it suggests a low affinity or 
suboptimal peptide can also activate T cells in the context of a dtSCT. Thus the dtSCT 
format has a great potential for broadening the application of SCT DNA vaccines for 
diseases in which critical antigenic peptides are weak binders to MHC. For example, 
many tumor associated antigens (TAA) show low immunogenicity because of low 
binding affinity to MHC I and this fact has limited the efficacy of cancer vaccines and 
immunotherapeutics [34]. A dtSCT strategy will increase the potency of a vaccine by 
increasing the level of MHC I/tumor epitope complexes on the antigen presenting cell 
surface. 
Future improvements using SCT based vaccines will require a better 
understanding of the mechanism by which they present antigen.  Indeed, the mechanisms 
by which DNA vaccines induce antigen specific immunity in vivo are under intense 
investigation. After the plasmid is delivered to the skin, subcutaneum or to the muscle 
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depending on the delivery method, it enters the nucleus of transfected cells using the host 
cellular machinery followed by expression of the antigen of interest [24]. Antigen 
presenting cells (APCs) play a dominant role in priming naïve antigen specific T cells by 
presenting MHC I/peptide complexes in combination with co-stimulatory molecules. 
Two models have been proposed for how APCs obtain and present antigens following 
DNA vaccination. It can be either direct transfection of professional APCs by the plasmid 
or cross-presentation of antigens transferred from transfected nonprofessional cells such 
as keratinocytes or myocytes to APCs [2, 33-39]. Our study provides evidence that SCTs 
are presented as intact molecules after immunization, suggesting that cross-presentation 
involving re-processing of antigens is not the major mechanism for antigen presentation 
after DNA vaccination. Gene-gun delivers plasmids to the epidermis where epidermal 
keratinocytes and also epidermal dendritic cells (Langerhans cells) can be directly 
transfected [34, 48, 93]. Langerhans cells were shown to migrate to draining lymph nodes 
and prime naïve CD8
+
 T cells efficiently [49]. Thus, in our case, professional APCs, i.e. 
dendritic cells (DCs), directly transfected with plasmids may express and present SCTs 
directly to T cells. Alternatively, APCs may obtain intact SCT molecules from 
transfected cells through intercellular transfer of cell surface molecules. This 
phenomenon of transfer of plasma membrane fragments including proteins between 
lymphocytes, called trans-endocytosis or trogocytosis, has been reported for a long time 
[51, 58-65, 164]. This process allows rapid transfer of intact cell surface proteins between 
cells in contact with one another and transfer of intact MHC/peptide complexes between 
APCs or from dying cells to APCs, recently termed ‘cross-dressing’, has been 
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demonstrated although the molecular processes involved need to be clarified. Relevant to 
our study, Ostrand-Rosenberg et al. reported that DCs utilize both cross-presentation and 
cross-dressing mechanisms to prime CD8
+
 T cells [59]. And Lechler et al. demonstrated 
in vitro that splenic CD8+ DCs can acquire MHC/peptide complexes from other DCs 
and stimulate CD8
+
 T cells [61]. More recently, Bevan et al. demonstrated that this cross-
dressing does occur in vivo during virus infection [58]. It is plausible to think SCTs are 
presented through a cross-dressing mechanism, considering that our data indicate 
presentation of intact SCT molecules and that it has been reported that targeting antigen 
presentation to DCs was insufficient to optimally prime T cells in gene gun DNA 
immunization [50]. Thus, in our case, DCs may present SCTs that are obtained from 
transfected epidermal keratinocytes or epidermal dendritic cells via a cross-dressing 
mechanism. In any case, our unique approach using SCTs adds to the growing evidence 
of the importance of intercellular transfer of intact MHC/peptide for T cell priming.  
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Chapter 5 
Concluding Remarks and Future Directions 
 
I have learned in my dissertation studies that unexpected results can sometimes be 
more insightful for future directions than expected results. More specifically for many 
experiments there are clear expectations or biases based on previously reported findings. 
However, during my dissertation research I came upon several instances where expected 
results were not obtained forcing us to re-think paradigms. In this final chapter I give 
three examples of my experiments that resulted in unexpected and unresolved findings; 
indeed the first two were unexpected negative findings. I then speculate on the 
significance of these findings and what might be done to resolve outstanding questions 
raised by these three observations. 
 
Unexpected diversity of TCR V chain usage of MAIT cells after MR1 selection 
The first unexpected findings concern MR1, the project I worked on when I 
joined the Hansen lab. MR1 is a class Ib MHC molecule that restricts the development 
and activation of a novel T cell subset referred to as MAIT (mucosal- associated invariant 
T) cells [165-167]. MR1 is remarkably conserved among mammalian species, especially 
in its 1 and 2 domains. Indeed, the 1/2 domains are 90% identical between human 
and mouse, suggesting an evolutionarily conserved function for MR1, perhaps binding a 
conserved ligand [168, 169]. Mouse MAIT cells express an invariant V19-J33 chain 
and limited V chains, preferentially V8.1, V8.2, or V6. Although MR1-restricted 
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MAIT cells have been recently implicated in bacterial responses [167], their mechanism 
of detection of bacteria is unknown. MAIT cells are one of only two mammalian T cell 
populations with an invariant TCR chain. The other invariant T cells are the extensively 
studied iNKT cells that recognize glycolipid antigens presented with CD1d molecules 
[170]. On the basis of the expression of an invariant TCR and the restriction to the highly 
conserved MR1 of MAIT cells, we hypothesized that TCR V chains of MAIT cells have 
limited diversity. To examine this, we determined the importance of the TCR V chain 
diversity of polyclonal mouse MAIT cells using a sequencing approach of the CDR3 
region. These studies were done with the expert advice of Dr. Chyi-Song Hsieh. 
Surprisingly, the usage of V chains of MAIT cells was highly diverse in both amino 
acid sequence and length of the CDR3 region. This result suggested that i) MAIT cells do 
not discriminate ligands, and/or ii) the orientation of the interaction of MAIT cell TCR 
and MR1 is different from that of conventional TCR and classical MHC I. It has been 
reported that iNKT cells are able to recognize many different self- and non-self 
glycolipid variants [87, 170, 171]. iNKT cells also express a limited number of TCR 
chains with variable CDR3 regions paired with an invariant V14-J18. Importantly, 
structural and mutational studies showed that the iNKT cell TCR uses the unique mode of 
antigen recognition where germline-encoded residues are involved in antigen recognition 
and CDR3 is unlikely to contact directly with antigens, indicating limited antigen 
discrimination [172-175]. Thus, my finding seemed to suggest that MAIT cells also may 
not discriminate antigens or CDR3 is not directly involved in antigen recognition. 
Recently, two groups reported that human and mouse polyclonal MAIT cells are 
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activated in an MR1-dependent manner by a wide variety of microbes including E. coli, 
Mycobacteria, Pseudomonas, Klebsiella, Lactobacillus, Staphylococcus, Saccharomyces 
and Candida, but not Streptococcus A and virus [176, 177], suggesting that MAIT cells 
have limited ligand discrimination. To elucidate the antigen recognition of MAIT cells, it 
will be critical to identify the nature of the MR1 ligand and whether it is a self-ligand 
induced by infection or a microbial ligand. Elution and characterization of the ligand 
from MR1 at the surface of cells infected with microbes should be able to answer to this 
question. 
 
Failure to construct a WNVp33/ D
b
 SCT even with a disulfide trap 
Our lab and others have made SCTs with several different human, mouse, or rat 
MHC I heavy chains bound by different antigenic peptides. The reported SCTs include 
ones made with the class Ib molecule HLA-E bound by two different antigenic peptides. 
Thus, we considered that the SCT was likely universally applicable prior to my findings 
that include the WNVp3/K
b
 SCT described in Chapter 4.1. Besides the WNVp3/K
b
 SCT, 
I found the D
b
 SCT that incorporates another immunodominant WNV epitope p33, 
SSVWNATTA, is also not recognized by T cells. More surprisingly, the recognition of 
WNVp33/D
b
 SCT was not improved by a disulfide trap. Even with a disulfide trap, this 
SCT appears accessible to the exogenous peptide because CTLs were able to kill the cells 
when WNVp33 was exogenously added to WNVp33/D
b
 dtSCT-expressing cells. To 
solve the problem, with advice from Dr. Fremont, I first tried mutation of the anchor 
residue of WNVp33 to increase the peptide binding to the groove. D
b
 binding peptides 
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usually have a hydrophilic C terminal residue, Met, Ile, or Leu, which WNVp33 does not 
have [178, 179]. Our hypothesis was that the mutation of P9 alanine to one of the 
common anchor residues might enhance the peptide binding and T cell recognition. 
However, my result showed that four different WNVp33 variant/D
b
 SCTs still do not 
activate T cells. Alternatively, I re-positioned the disulfide trap using either Thr
80
 or Tyr
84
 
in the heavy chain and Gly
1
 or Gly
2
 in the peptide-2m linker to find a better 
combination to provide the best anchoring of peptide. Thr
80
 in the heavy chain locates at 
the C terminal end of the peptide binding groove along with Tyr
84
 and studies in our lab 
previously showed that a disulfide trap using this residue did not alter the surface 
expression or antibody recognition of the K
b
/OVAp SCT [23]. But to our disappointment, 
none of the disulfide trap locations made WNVp33/D
b
 SCT refractory to exogenous 
peptide binding nor did they promote T cell detection. The failure of this SCT is still 
puzzling to us, but clearly indicates that not every MHC I/peptide complex can be made 
as a SCT without modifications. To resolve the problem with WNVp33/D
b
 SCT, detailed 
analyses of the SCT at the cell surface such as conformation, 2m binding, and the linker 
association might be helpful. Also different lengths of the peptide-2m linker and/or 
combinations of the approaches that have been tried above may need to be considered. 
Resolution of this enigma may provide novel insights into peptide binding to MHC 
proteins or at least to the D
b
 allele. 
 
Implication of intercellular membrane exchange in Ag presentation following DNA 
vaccine 
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Our data supporting the importance of intercellular membrane exchange as a 
mechanism for cross-presentation following DNA vaccination was unexpected based on 
its inefficiency. Membrane exchange between cells, frequently referred to as 
trogocytosis, has been reported in cellular interactions such as APCs with T cells or NK 
cells [64]. However, in these examples the membrane transfer is receptor-mediated, i.e. 
MHC transfer from APCs to T cells by the TCR or to NK cells by the Ly49 receptors. If 
membrane exchange is involved in the antigen presentation after DNA vaccination by 
gene gun, it presumably involves transfer of MHC/peptide complexes from the cells 
taking up the DNA to the APCs that prime the CD8
+
 T cells.  
Accumulating reports in the literature document the importance of cross-
presentation in vivo as a mechanism for detection of pathogens and tumors [55-57]. Also 
significant is recent evidence suggesting that the APCs required for priming of CD8
+
 T 
cells are LN resident CD8+ DC [56]. In addition, a recent report in Science from the 
Murphy lab clearly demonstrates the in vivo importance of CD8+ DCs in responses to 
pathogens and tumors in that T cell responses are absent in Batf3-deficient mice that 
specifically lack CD8+ DCs [54]. Their findings define the critical importance of this 
cell type for physiologic cross-presentation. Thus the initial outstanding questions are 
which cells express the antigen after DNA vaccination and which cells transfer the 
antigen to the CD8+ DCs. From studies of the cross-presentation after subcutaneous 
virus infection, a current model is that a migratory DC transports the antigen from the 
skin to the regional LN where it is then transferred to the CD8+ DC for activation of 
CD8
+
 T cells [55, 56]. However, what is unclear in this model is how antigens are 
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efficiently transferred between cells. Most studies probing the mechanism of cross-
presentation have used in vitro approaches to address the cellular processes that allow 
APCs to take up exogenous antigens and transfer them to the cytosol where TAP 
transports the antigens into the ER to compete with other peptides for loading into MHC I 
molecules. This mechanism of re-presentation of the antigen is very unlikely to be 
efficient particularly because most current in vivo models of cross-presentation require 
multiple transfers between different cells, making it difficult to achieve sufficient levels 
of the surface antigen display to activate CD8
+
 T cells.  
Could the transfer of intact MHC/peptide complexes represent a more efficient 
mechanism of cross-presentation than re-presentation of the antigen between different 
cells? Conceptually, it might seem so because transfer of an intact MHC/peptide complex 
bypasses inefficiencies of retro-grade intracellular transport into the ER as well as 
competition within the ER for peptide loading. However, based again solely on in vitro 
assays, the transfer of intact MHC/peptide complexes between cells (i.e cross-dressing) 
appears marginal at best [62, 63]. Typically, in these in vitro membrane exchange assays, 
freeze/thaw lysates of the antigen-fed cells of one MHC haplotype are incubated with 
cells of an alternative MHC haplotype. CD8
+
 T cells specific for the donor MHC/antigen 
are then used to monitor exchange of the intact MHC/peptide molecules. It is noteworthy 
that in these in vitro assays the level of MHC/peptide complexes that are exchanged is 
barely detectable by FACS. Thus, like with conventional cross-presentation mechanisms, 
the efficiency of the transfer of intact MHC/peptide complexes seems marginal.  
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What has been missing is in vivo evidence that cross-dressing is an important 
mechanism of CD8
+
 T cell activation. In this regard, the recent paper by Wakim and 
Bevan is important in that they make several relevant observations [58]. First, they 
showed that cross-dressing is 3 orders of magnitude less efficient than the direct 
presentation by donor DCs for inducing proliferation of naïve or memory T cells.  They 
then used the diphtheria toxin system to eliminate the cross-dressed DCs and showed data 
implicating cross-dressing in expansion of resting memory cells and not naïve cells. 
Somewhat surprisingly, they also report that CD4
+
 DCs are the subset involved in cross-
dressing. These intriguing findings certainly help to focus future investigations on the in 
vivo mechanism of cross-dressing. 
As reported here in Chapter 4.2, we took a unique approach to study the 
importance of cross-dressing using SCT-based DNA vaccines. Our rationale was, if SCTs 
really are superior to the peptide or minigene based vaccines, then they are presumably 
presented by APCs to CD8
+
 T cells as intact structures. Mechanistically, this would 
imply either that the APC taking up the plasmid encoding the SCT directly presents the 
SCT, or that the SCT is transferred from the cell making the SCT protein to a DC capable 
of CD8
+
 T cell activation. It is also noteworthy that in collaboration with the Gillanders 
and Murphy labs we have shown that CD8+ DCs are required for gene gun DNA 
vaccination in general and SCT-based vaccination specifically. Thus, like other models 
where cross-presentation has been implicated, the CD8+ DC appears to be the requisite 
APC. Our evidence that SCTs are presented as intact structures is based on the two 
different lines of evidence (Chapter 4.2 and unpublished observations from the 
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Gillanders’ lab).  First, a mutation in the SCT that blocks TCR or CD8 engagement 
ablates its ability to prime T cells after DNA vaccination. Second, the SCTs with poor 
binding peptides that cannot be re-presented elicit robust CD8
+
 T cell responses after 
DNA vaccination. Although our findings like the aforementioned Wakim and Bevan’s 
study support the importance of cross-dressing, they have significant differences. Most 
notably, our findings, in contrast to theirs, suggest the importance of cross-dressing for 
priming naïve CD8
+
 T cell responses and implicate the importance of CD8+ DCs in 
cross-dressing. 
Thus there are several outstanding questions where SCT approaches can be used 
to address mechanisms of cross-presentation in CD8
+
 T cell responses including DNA 
vaccination. Because of the published disconnect between the in vitro and in vivo 
evidence regarding mechanisms of cross-presentation, it will be critical to focus future 
studies on in vivo approaches. For example, in the OT-1 model, expression of OVAp/K
b
 
SCTs to certain cell types using different promoters and expressing SCTs that can or 
cannot (OVAp5Y/K
b
) be cross-primed may be informative for addressing mechanistic 
questions. For example, this approach might be useful for determining which cells 
express the SCT after DNA vaccination and which APCs are required for priming naive 
vs. memory CD8
+
 T cells. This approach might also be used to address the relative 
importance of cross-dressing vs. peptide re-presentation. It might also be insightful to use 
in vivo imaging to track the SCT following DNA vaccination.  
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